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Abstract
With few exceptions, intensive care unit (ICU)-based randomized clinical trials (RCTs) have failed to
demonstrate hypothesized treatment effects. Undoubtedly, some of these failures are attributable to
interventions that truly do not provide hoped-for benefits. However, this dissertation pursues the thesis
that many null findings represent “false negatives” that are due not to ineffective therapies but to flawed
study designs or analytic approaches. We examine the design and statistical methods traditionally
employed in ICU-based RCTs, and their potential impacts on the efficient measurement and interpretation
of treatment effects. Paper one presents a systematic review of 146 contemporary ICU-based RCTs in
which we find that most trials were underpowered to detect small but potentially important mortality
differences between treatment arms. We also find that the majority of RCTs (73%) specified primary
outcomes other than mortality, that trials employing nonmortal primary outcomes more frequently
identified significant treatment effects, and that both mortal and nonmortal endpoints were
heterogeneously defined, measured and analyzed across RCTs. Thus, papers two and three focus on
nonmortal endpoints, using ICU length of stay (LOS) as a case study to evaluate how best to measure and
analyze duration-based nonmortal endpoints. In paper two, we conduct a statistical simulation study,
demonstrating that nonmortal endpoints are interlinked with and confounded by mortality, and that the
manner in which investigators choose to account for deaths in LOS analyses may influence their
conclusions. In paper three, we examine another potential source of error in LOS analyses, namely the
measurement error attributable to the additional ICU time that patients commonly accrue after they are
clinically ready for ICU discharge. Using simulated data informed by our own ICU-based RCT, we
demonstrate that this “immutable time” (which cannot plausibly be altered by the interventions under
study) combines with clinically necessary ICU time to produce overall LOS distributions that may either
mask true treatment effects or suggest false treatment effects. Our work provides evidence of the
potential benefits and pitfalls when employing nonmortal outcomes in ICU-based RCTs, and also
identifies a clear need for standardized methods for defining and analyzing such outcomes.
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ABSTRACT

ENDPOINTS IN INTENSIVE CARE UNIT BASED RANDOMIZED CLINICAL TRIALS
Michael Oscar Harhay
Scott David Halpern

With few exceptions, intensive care unit (ICU)-based randomized clinical trials (RCTs) have failed
to demonstrate hypothesized treatment effects. Undoubtedly, some of these failures are
attributable to interventions that truly do not provide hoped-for benefits. However, this dissertation
pursues the thesis that many null findings represent “false negatives” that are due not to
ineffective therapies but to flawed study designs or analytic approaches. We examine the design
and statistical methods traditionally employed in ICU-based RCTs, and their potential impacts on
the efficient measurement and interpretation of treatment effects. Paper one presents a
systematic review of 146 contemporary ICU-based RCTs in which we find that most trials were
underpowered to detect small but potentially important mortality differences between treatment
arms. We also find that the majority of RCTs (73%) specified primary outcomes other than
mortality, that trials employing nonmortal primary outcomes more frequently identified significant
treatment effects, and that both mortal and nonmortal endpoints were heterogeneously defined,
measured and analyzed across RCTs. Thus, papers two and three focus on nonmortal endpoints,
using ICU length of stay (LOS) as a case study to evaluate how best to measure and analyze
duration-based nonmortal endpoints. In paper two, we conduct a statistical simulation study,
demonstrating that nonmortal endpoints are interlinked with and confounded by mortality, and
that the manner in which investigators choose to account for deaths in LOS analyses may
influence their conclusions. In paper three, we examine another potential source of error in LOS
analyses, namely the measurement error attributable to the additional ICU time that patients
commonly accrue after they are clinically ready for ICU discharge. Using simulated data informed
by our own ICU-based RCT, we demonstrate that this “immutable time” (which cannot plausibly
be altered by the interventions under study) combines with clinically necessary ICU time to
produce overall LOS distributions that may either mask true treatment effects or suggest false
treatment effects. Our work provides evidence of the potential benefits and pitfalls when
employing nonmortal outcomes in ICU-based RCTs, and also identifies a clear need for
standardized methods for defining and analyzing such outcomes.
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CHAPTER 1. INTRODUCTION

The growing burden and cost of critical illness
The demand for critical care, both in the United States (US) and worldwide, is outpacing
the discovery of interventions that can substantively improve outcomes in intensive care unit
(ICU) settings. In the US, one third of hospitalizations among patients older than 65 includes an
ICU stay (Milbrandt et al., 2008) and 20% of the US population dies in an ICU (Angus et al.,
2004). The global demand for and provision of critical care will likely grow in future years, both
because of aging populations where ICUs are prevalent as well as the expansion of critical care
in lower-income settings (Cook & Rocker, 2014; Fleischmann et al., 2016; Murthy et al., 2015).
The processes that lead to critical illness are diverse, which presents a challenge for
researchers seeking to study and compare interventions in homogeneous ICU patient
populations. Two paradigmatic examples of critical illness commonly encountered in ICU settings
are sepsis/septic shock (Singer et al., 2016) and the acute respiratory distress syndrome (ARDS)
(Force et al., 2012), both of which can result from acute or chronic illness and may present in a
variety of patient types (e.g., various ages, comorbid conditions). ICUs also provide life-saving
care for patients who are critically ill after surgery or trauma, as well as for a heterogeneous mix
of patients with other pathologies (e.g., cardiovascular disease, cancer).
Despite the diversity inherent in critical care settings, one unifying theme of critical illness
is its high cost, both in financial and human terms. In the US, 1% of the gross domestic product is
spent on the provision of critical care, exceeding $80 billion per year, and representing
approximately 3% of all health care spending (N. A. Halpern et al., 2016; N. A. Halpern &
Pastores, 2010). In addition to the financial burden, survivors of critical illness are often left with
physical, cognitive and psychosocial deficits that impede long-term quality-of-life (QOL) (Adhikari
et al., 2011; Bienvenu et al., 2012; Fan et al., 2014; Herridge et al., 2011; Iwashyna, 2010; Kress
1

& Hall, 2014; Mikkelsen et al., 2012; Spragg et al., 2010). There is also a growing awareness of
the downstream impact of critical illness on patients’ caregivers, family members, and friends,
who are called upon to cope with the loss of their loved ones after witnessing their suffering, or to
provide daily care to survivors who require prolonged periods of time to regain their
independence (Azoulay et al., 2005; Cameron et al., 2016; C. E. Cox et al., 2009). For instance,
roughly one third of decision-makers for critically ill patients develop post-traumatic stress
disorder or complicated grief that lasts months to years (Azoulay et al., 2005; Wendler & Rid,
2011). Finally, there is the lasting impact on the critical care workforce (i.e., physicians and
nurses) who must face death frequently and often report on the futility of the care they deliver,
resulting in high rates of burnout (S. D. Halpern, 2011b; Hamric & Blackhall, 2007; Meltzer &
Huckabay, 2004; Piers et al., 2011).
Given the burden and costs of critical illness, innovations that improve outcomes among
the critically ill have the potential to make vast impacts. Indeed, there is an impetus to advance all
aspects of critical care, from the delivery of cost-effective care to the improvement of patientcentered outcomes including quality-of-life. However, studies investigating promising therapies
and clinical interventions in ICU settings have met with limited success, a topic that will be further
illustrated in the second chapter of this dissertation.

Randomization inference
Randomized clinical trials (RCTs) are considered the “gold standard” for producing the
experimental evidence required to assess the efficacy and safety of interventions. The pursuit of
an RCT-generated evidence base pervades all medical disciplines, and more recently has
extended into the social sciences. This is because randomization, or randomly allocating patients
to a study arm, probabilistically balances study arms on all pretreatment or baseline factors
(measured and unmeasured) and thereby is able to mitigate the likelihood of selection biases
2

when conducting hypothesis tests that compare study arms on post-randomization outcomes. As
a result, random assignment of an intervention supports an estimate of the treatment effect that is
independent of the error term. The result is an unbiased estimate of the impact of an intervention.
The attractions and benefits of an RCT over observational data to assess a hypothesis
have been written about widely and presented in various frameworks over the past several
decades. The counterfactual framework is useful for describing why RCTs are so highly valued in
developing theories of causal inference between exposures and outcomes (Hernán & Robins,
2016; Morgan & Winship, 2015). Specifically, let A denote an exposure to an intervention in the
ICU (A=1 indicates exposure to an intervention and A=0 indicates no exposure to an
intervention). Then, for a binary outcome Y (e.g., death at day 30), we say that the intervention
(A) has a causal effect on Y if Probability(Pr)[Ya=1=1] ≠ Pr[Ya=0=1] and the intervention has no
causal effect on Y (the null hypothesis) if Pr[Ya=1=1] = Pr[Ya=0=1]. Indistinguishable notation would
be applied to any ICU outcome of interest regardless of if it was a continuous (e.g., length of stay
[LOS]), time-to-event (e.g., time-to-resolution of delirium) or count (e.g., days of infection per
1,000 patient days) distribution.
In observational research, there is a concern about known and unknown (or observed
and unobserved) confounders. The theory behind randomization is that if it is executed correctly,
the concern about confounding at baseline is removed. Without randomization prior to exposure,
there is no guarantee that A, representing the intervention, is uncorrelated with the error term, ε
(i.e., A may be endogenous). The result of endogenous correlation is a potentially biased, or
incorrect estimate of the impact of an intervention.
In contrast, the randomized experiment is built upon the concept of exchangeability,
which by design is not susceptible to endogeneity. As a result, execution of an RCT is the closest
a scientist can get to producing an unbiased causal effect estimate. Specifically, the risk of an
event at baseline under the potential treatment value a among the treated is equal to the risk
under the potential treatment value a for the untreated Pr[Ya=1|A=1] = Pr[Ya=1|A=0]. Said
3

differently, the conditional risk of an outcome is equal in all subsets defined by treatment status in
the population. Therefore, the baseline risk is equal to the marginal risk under treatment value a
in the whole population. In ideal settings the process of randomization or random allocation
should result in counterfactual data that is missing completely at random (MCAR) for each
subject, such that causal effects can be estimated statistically without bias.
In practice, various logistical, patient and post-randomization factors can erode the
assurance of unbiased effect estimates. Indeed, the focus of Chapters 4 and 5 of this dissertation
are on post-randomization factors that can bias randomization inference. Specifically, in Chapter
4 we assess the impact of informative censoring from mortality, and in Chapter 5 we assess
measurement error resulting from within-hospital patient flow and how these post-randomization
processes can bias treatment effect estimates and interpretation.

Experimental evidence for treating critical illness
Efforts at improving critical care outcomes have resulted in a long history of ICU-based
RCTs that have been unable to demonstrate statistically significant improvements in patient
outcomes through new interventions, protocols, therapies and staffing models in the ICU
(Aberegg et al., 2010; Angus et al., 2010; Annane, 2009; Ospina-Tascon et al., 2008). Exceptions
include studies that have shown the benefits of low (rather than high) tidal volumes for patients
receiving mechanical ventilation (ARDSnet Investigators, 2000), of restrictive (rather than
aggressive) blood transfusion practices (Hebert et al., 1999; Villanueva et al., 2013), and of light
sedation that is frequently interrupted (rather than heavy sedation without protocol-driven
interruptions) to maintain comfort among ventilated patients (Girard et al., 2008; Kress et al.,
2000). Unfortunately, the vast majority of critical care RCTs have not demonstrated interventions
that decreased mortality (Aberegg et al., 2010; Landoni et al., 2015; Ospina-Tascon et al., 2008).
A review of RCTs published exclusively in the journal Intensive Care Medicine from 2000-2010
4

found an overall success rate of 48.8% (of 221 RCTs) (Latronico et al., 2013). However, in two
reviews of RCTs where mortality was the primary endpoint, success rates were only 14% (10 of
72 RCTs published before August 2006) (Ospina-Tascon et al., 2008) and 18% (7 of 38 RCTs
published from 1999-2009 in 5 major medical journals) (Aberegg et al., 2010), respectively. Given
that these studies all focused on published RCTs, the true rate of positive RCTs is potentially
lower as negative studies, especially industry-sponsored trials, may be less likely to be submitted
for publication or ultimately be accepted for publication. The low rate of successful ICU-based
RCTs has not gone unnoticed; there are some thought leaders who have been so disappointed
by these trends that they have suggested entirely abandoning the concept of RCTs in the ICU
(Dreyfuss, 2004; J.-L. Vincent, 2010). However, it is unclear whether the majority of ICU-based
RCTs were negative because of a true lack of treatment effect or because of the design elements
of the RCTs in which they were tested (J. L. Vincent, 2009). This is especially relevant in studies
of nonmortal clinical endpoints (e.g., LOS in the ICU), where the statistical handling of dropout
(censoring) from death could impact the interpretation of results. Therefore, this dissertation
seeks to expand the empirical solutions available to researchers to help in distinguishing negative
versus misinterpreted trials. To do so, we build on a small and limited empirical foundation.
While there is a range of proposed explanations (see conceptual framework in Table 1.1)
for the low success rates of ICU-based RCTs, empirical research has focused almost exclusively
on explanations related to statistical power in mortality studies. Specifically, researchers have
identified a practice termed delta inflation, wherein unrealistically large predicted treatment effects
are used to estimate a trial’s needed sample size (Aberegg et al., 2010; Latronico et al., 2013).
Conversely, detection of smaller (but possibly more realistic) mortality differences between study
arms requires larger study samples. As a result, studies that are powered based on delta inflation
may be perceived as inconclusive or negative because potentially clinically relevant treatment
effects are not statistically significant. The empirical assessment of delta inflation bias has been
restricted to RCTs of mortality. It is unclear if this practice occurs with other nonmortal primary
outcomes, and further, if nonmortal endpoints are as frequently negative as studies powered to
5

detect a treatment-associated decline in mortality. It is also unclear if misspecification of other
elements of the power calculation, such as the event rate in the control arm of the study, leads to
underestimated necessary sample sizes. These specific questions are examined in Chapter 2.
This thesis also pursues a specific focus on nonmortal outcomes which are largely underscrutinized but increasingly advocated trial endpoints by investigators and trial consortiums
(Mebazaa et al., 2016; Opal et al., 2014; Spragg et al., 2010; Young et al., 2012). Principal to this
endeavor is the identification and subsequent standardization of core outcomes that will be
measured and analyzed identically across future trials to promote less biased comparisons
between different trials and promote harmonized data assemblage in meta-analyses (Blackwood
et al., 2014; Blackwood et al., 2015). This area of research activity is very nascent in critical care,
but has seen much activity in other disciplines through the COMET (Core Outcome Measures in
Effectiveness Trials) Initiative which focuses on the development and application of a
standardized set of outcomes (Prinsen et al., 2014; Williamson & Clarke, 2012). Among the
several goals of this work, the research herein seeks to enhance research in critical care by
considering standardized analytic methods to improve the detection of clinically relevant
treatment effects and facilitate comparisons across ICU populations worldwide.

Dissertation aims
As reviewed above, RCTs among critically ill patients commonly fail to detect their
hypothesized treatment effects, but it is unknown whether these trials have correctly identified the
lack of treatment effect (i.e., true negative) or have committed a type-II error (i.e., false negative)
due to methodologic flaws. Therefore, this dissertation seeks to evaluate the hypotheses outlined
in Table 1.1. The overall objective is twofold: (1) to provide and advance knowledge that will
improve current approaches to designing RCTs in critical care and (2) advance novel
perspectives and concepts to improve the assessment of experimental evidence from ICU-based
6

RCTs. These two goals are collectively accomplished through a series of three thematically linked
analyses that elucidate some of the potential mechanisms underlying the ongoing challenges that
past trials have encountered in identifying treatment effects.
First, in Chapter 2, we conduct the largest-ever study of the outcomes, design, and
analysis of ICU-based RCTs published in 16 leading journals from 2007-2013. In Chapter 3, we
present the empirical framework for Chapters 4 and 5, which is based on the finding that the
majority of RCTs studies in Chapter 2 were designed to assess a nonmortal primary endpoint.
Therefore, Chapters 4 and 5 focus on issues salient to RCTs with nonmortal endpoints, and use
ICU LOS as a case study. Indeed, LOS is the most frequently used nonmortal outcome across all
published trials (Chapter 2), and both a patient-centered and critical operational outcome. It is
also representative of a broader class of endpoints assessing “durations,” such as the duration of
organ dysfunction, delirium, or ventilation. Accordingly, LOS is an illustrative endpoint to appraise
the empirical and conceptual issues related to the definition, measurement and statistical
comparisons of nonmortal measures between study arms.
First, in Chapter 4, a detailed examination of the epidemiological and statistical issues of
measuring and analyzing ICU LOS in the presence of informative censoring due to mortality is
undertaken. Then, in Chapter 5 we identify and evaluate the importance of a new form of
measurement error termed ‘immutable time bias.’ This bias is defined as immutable because the
extra time contributed to the total LOS could not be altered by the intervention, but rather is driven
by system issues including floor bed availability, capacity strain, or administrative delays. With a
simulation study informed by both the Study to Understand Nighttime Staffing Effectiveness in a
Tertiary Care ICU (SUNSET-ICU) RCT, performed at our institution, and the few other RCTs we
identified that reported the “ready-to-discharge time” over “actual discharge time,” we assess the
identification of treatment effects in LOS under different hypothetical scenarios. We summarize
the results of these three empirical investigations and their relevance for future ICU-based RCTs
in Chapter 6.
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Table 1.1. Hypotheses to explain low efficacy in critical care randomized clinical trials

Domain

Dissertation
chapter
assessing an
element of this
hypothesis

Intervention

2

Logistical

2,5

Study
population

2,4,5

Power

2,4,5

Outcome

2,4,5

Analysis

2,4,5

Hypothesis

The proposed interventions are not truly effective
interventions.
RCTs are sufficiently powered but patient attrition
leads to appreciable post-randomization losses so
that the intention-to-treat analyses are highly
conservative or biased.
Treatment-effect heterogeneity may lead to a diluted
effect estimate because while interventions work for
certain patients, others are too sick and/or have too
many competing risks for death for singular
interventions to be of benefit.
RCTs may suffer design issues, such as insufficient
power to detect relatively small but important effects
in appropriate outcomes (i.e., excessive Type II error
rates).
Outcome measures are inappropriate, that is, the
intervention does not impact the outcome that is
measured or the selected outcome is not the ideal
way of measuring an effect.
Outcome measures themselves are appropriate,
however, the mathematical methods of evaluating
them are flawed or limited.
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CHAPTER 2. OUTCOMES AND STATISTICAL POWER IN ADULT CRITICAL CARE
RANDOMIZED TRIALS

This chapter has been published in the American Journal of Respiratory and Critical Care
Medicine, official journal of the American Thoracic Society, and is reprinted here with permission
of the American Thoracic Society. Copyright © 2014 American Thoracic Society. The citation for
this publication is:
Harhay MO, Wagner J, Ratcliffe SJ, Bronheim RS, Gopal A, Green S, Cooney E,
Mikkelsen ME, Prasad Kerlin M, Small DS, Halpern SD. 2014. Outcomes and Statistical
Power in Adult Critical Care Randomized Trials. American Journal of Respiratory and
Critical Care Medicine Jun 15;189(12):1469-78.
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Introduction
In this chapter we examine the design, analysis and outcomes used in published ICUbased RCTs. As noted in the introduction, the primary motivation for this analysis is that most
published RCTs of critical care interventions that aim to reduce mortality have produced negative
results (Aberegg et al., 2010; Angus et al., 2010; Annane, 2009; Ospina-Tascon et al., 2008), and
even these reports may be overly optimistic because negative trials are less likely to be published
and identified. While several RCTs have revolutionized critical care practice (ARDSnet
Investigators, 2000; Girard et al., 2008; Guerin et al., 2013), the results of critical care trials on the
whole have been so disappointing that some leaders in the field have suggested a renewed focus
on non-experimental study designs (Dreyfuss, 2004; J.-L. Vincent, 2010).
However, truly negative trials are valuable because they prevent the use of interventions
that are either costly but non-beneficial or even harmful (e.g., intensive insulin therapy (Van den
Berghe et al., 2006) and hydroxyethyl starch (Myburgh et al., 2012; Perner et al., 2012)). Further,
there are many reasons why trials may not demonstrate a treatment effect, including ineffective
interventions, difficulty recruiting adequate sample sizes, post-randomization patient attrition,
heterogeneous patient populations or treatment-effect heterogeneity, use of inappropriate
outcomes, unreasonable assumptions (e.g, predicted effect sizes) used in power calculations
and/or smaller than appreciated attributable morbidity and mortality fractions (Aberegg et al.,
2010; Angus et al., 2010; Annane, 2009; Marini, 2006; McAuley et al., 2010; Ospina-Tascon et
al., 2008; Reade & Angus, 2009; Rubenfeld & Abraham, 2008; van Meurs et al., 2008).
Understanding an evidence base requires the ability to distinguish among these reasons so as to
differentiate trials that are truly negative from those that may be falsely negative.
As a first step in enhancing understanding of clinical trials in adult critical care, we
created a contemporary database of the design, analysis, and reporting of ICU-based RCTs.
Herein, we describe the development of this database, the characteristics of RCTs published in
the past 6 years with a specific focus on the outcome measures used, the quality of these RCTs
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using selected quality metrics, and the extents to which several issues germane to statistical
power may contribute to trials’ outcomes.

Methods
A group of physicians, epidemiologists and statisticians, guided by the 2007 CONSORT
(Hopewell et al., 2008) (Consolidated Standards of Reporting Trials) statement, Jadad scale
(Jadad et al., 1996; Juni et al., 2001), and prior work and commentaries on the topic (Aberegg et
al., 2010; Angus et al., 2010; Annane, 2009; Chiche & Angus, 2008; Marini, 2006; McAuley et al.,
2010; Ospina-Tascon et al., 2008; Reade & Angus, 2009; Rubenfeld & Abraham, 2008; van
Meurs et al., 2008; J.-L. Vincent, 2010) identified RCT elements to be abstracted. We began our
search for published RCTs in January 2007, as this approximated the end of prior review periods
(Aberegg et al., 2010; Ospina-Tascon et al., 2008) through May 2013. We examined only RCTs
of diagnostic, therapeutic, or process and systems interventions among adult patients conducted
in an ICU published in 16 prominent general or critical care journals (Table 2.1).
Table 2.1. Eligible journals and published critical care randomized clinical trials abstracted
Peer-reviewed journal
Number of RCTs
Critical Care Medicine
44
Intensive Care Medicine
20
JAMA
17
New England Journal of Medicine
17
American Journal of Respiratory and Critical Care
14
The Lancet
10
Medicine
Chest
7
Anesthesia and Analgesia
4
Anesthesiology
2
Annals of Internal Medicine
2
Archives of (now JAMA-) Internal Medicine
2
British Journal of Anesthesia
2
Canadian Medical Association Journal
2
British Medical Journal
1
Journal of Critical Care
1
Journal of Trauma and Acute Care Surgery
1
11

The MeSH terms “Intensive Care Unit”, “Critical Care”, “Critically Ill”, “Intensive Care”,
“ICU”, “Randomized clinical trial”, and “Randomized controlled trial” were combined with the
unique search names for the targeted journals. Search filters were used to limit our search to
studies of adults that were published in the English language. The search results were screened
for duplicates using RefWorks (ProQuest; Ann Arbor, MI) to create a single list of unique articles
for eligibility screening.
For an RCT to be considered eligible it had to: (i) be published in one of the sixteen prespecified journals no earlier than 2007, (ii) take place in one or more ICUs (i.e. not in an
emergency department, post-anesthesia recovery unit, or elsewhere), (iii) include adult patients,
and (iv) specify a primary clinical outcome (Table 2.2).

Table 2.2. A priori selected outcomes
1. ICU mortality

12. Duration of mechanical ventilation

2. In-hospital mortality

13. Organ failure-free days

3. 28-day mortality

14. Patient, family, physician, nurse, or
other provider satisfaction

4. 29-180 day mortality
15. Complications/ adverse outcomes
5. 181+ day mortality
16. Healthcare associated infections
6. ICU readmission
17. Quality of life
7. Hospital discharge disposition
18. Survival
8. Costs/ Charges
19. Incidence of acute organ failure
9. ICU length of stay
20. Delirium
10. Hospital length of stay
21. Composite or other outcome (not
previously specified)

11. Ventilator-free days
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We excluded intermediate and physiologic outcomes because our goal was to identify
trials testing interventions that were sufficiently mature as to be applied clinically as opposed to
those that were primarily hypothesis generating. Physiological and psychological test scores were
not considered to be clinical outcomes and hence were not abstracted. Intermediate and
physiologic outcomes were excluded because our goal was to identify trials testing interventions
that were sufficiently mature as to be applied clinically as opposed to those that were primarily
hypothesis generating.

Data abstraction
Using the Research Electronic Data Capture (REDCap) platform hosted at the University
of Pennsylvania (Harris et al., 2009), two investigators independently abstracted the primary and
secondary outcomes, as reported by the authors in each trial, and the result (positive or negative)
for each RCT. We relied on the data as reported by the original authors in their publication for
each study during abstraction. Three investigators (RB, AG, SG) served as primary data
abstractors, with two of them initially screening each article identified by the electronic search for
initial eligibility. To validate this screening process and as an internal quality measure, four other
investigators (MOH, JW, EC, and SDH) screened four of the sixteen selected journals over the
full duration of the inclusion period (n=951 journal issues). This screening identified 24 RCTs, of
which 18 were eligible per inclusion criteria. The 3 primary data abstractors achieved perfect
agreement, identifying all 24 of these RCTs and correctly excluding the 6 ineligible trials.
A superiority study was considered positive if the p-value for the analysis of the primary
outcome was less than 0.05, or the adjusted significance level after interim analyses, based on
the reporting in each RCT. An equivalence or non-inferiority study was considered positive if the
difference between study arms fell between the pre-determined margins (confidence intervals)
and met the equivalence or non-inferiority hypothesis at the p-value declared by the study’s
authors. When a study had more than two arms, outcomes were recorded from the control arm
and the arm employing an intervention of maximal dose or degree. Data were also extracted on
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study funding, type of intervention tested, target patient population, enrollment and retention, and
statistical power.
To assess statistical power, we abstracted three specific methodological elements: (1)
discussion of the power calculation used for the trial, (2) rationales for the parameters used in the
sample size or power estimation, and (3) participant accrual. Discussion of the power calculation
was defined as reporting the inputs used to calculate power or sample size, such as the baseline
(control group) event rate and the expected treatment effect size for binary endpoints. The
rationales for sample size or power estimation inputs could include prior research results, pilot
studies, or other objective data. Participant accrual was tracked by assessing CONSORT
diagrams, when available, indicating the number of patients screened, randomized and ultimately
analyzed (Hopewell et al., 2008).
The data abstractors achieved greater than 90% agreement for individual data elements,
including primary and secondary outcomes, funding, target sample size, and reason(s) for study
exclusion. The first author adjudicated the discrepancies that arose. STATA 13 (StataCorp,
College Station, Texas) was used for database management and analysis.

Analyses to assess statistical power
For each RCT with a binary outcome, we abstracted the predicted and observed risk
difference on the absolute scale. We used the absolute, rather than relative, risk difference
because absolute differences are used to determine the clinical significance of effects (Sackett et
al., 1997). For example, to calculate the number needed to treat, the absolute risk reduction is
required. For negative trials, we evaluated whether (non-significant) reductions in the primary
outcome of 3% or greater were identified. Our choice of a 3% cutoff is somewhat arbitrary, but
was chosen a priori based on the view that any treatment-associated absolute effect of this size
would clearly be important to patients, and that effects less than 3%, albeit potentially important,
could also more easily be attributable to noise or random error. These assessments were limited
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to trials that reported power calculations, so as to enable uniform determinations of whether or
not these RCTs were powered to document these effect sizes as significant.
We also explored the related phenomenon of “delta inflation bias” (Aberegg et al., 2010;
Latronico et al., 2013), whereby unrealistically large treatment effects are predicted in power
calculations, resulting in target sample sizes that may fail to detect clinically important differences.
To estimate the necessary sample size for a trial there are two essential components, the rate of
the outcome in the control arm and the expected difference, termed the minimally clinically
important difference (MCID). The MCID is also known as the predicted treatment effect, effect
size or delta ( D ). The MCID characterizes the smallest change in the primary outcome that is felt
to be meaningful to both the clinician and patient. The MCID is the most variable and important
component of sample size calculations, even when the outcome upon which the trial is powered
is the same across studies. To properly design a RCT that can adequately answer the primary
study question, it is necessary to establish the magnitude of the difference in the primary end
point that will signify a clinically relevant treatment effect. Detection of a smaller difference
between study groups requires larger sample sizes. Detection of a larger difference between
study groups requires smaller sample sizes. This mathematical tension is the speculated
motivation for researchers to select a larger threshold that consequently decreases the sample
size requirements. This is delta inflation (Aberegg et al., 2010). The corollary of this practice is the
increased likelihood of type II error (not detecting a true effect).
To understand how delta inflation works we can see below that if we seek to determine
the targeted sample size (n) using significance level 𝛼, (typically 0.05) and want to have power
1 − 𝛽 (typically 0.80) when we an assumed value for 𝑃1 (baseline mortality) & unknown value for

p 2 (mortality in the treated arm), a speculated mortality decline must be presumed. This decline
creates that delta, that is, ∆ = 𝑃1 − 𝑃2. These components permit the calculation of a targeted
sample size based on that delta using the following equation that can be calculated in most
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certain sample size range will be available the delta can be manipulated to attain an acceptable
power (e.g, 0.80). This can be seen in an alternative configuration of the above equation that can
be used to solve for a certain power. For instance, if we must use specific sample sizes n1 & n 2 ,
the assumed values for 𝑃1 & 𝑃2, and hence ∆ = 𝑃1 − 𝑃2 , can be changed and then the power we

achieve is given by:

p

where

n1 p1  n 2 p 2
n1  n 2 .
Using the actual enrolled sample sizes in the control and treatment arms, and the

observed baseline mortality rate, we calculated the power of each study to observe a clinically
significant, treatment-associated mortality reduction from of 3% to 15%. The number of trials with
80% power was tallied for each treatment-associated mortality reduction of 3% to 15%. We then
re-did each calculation using the predicted baseline mortality from the published RCT.
Comparison of power obtained using the observed and predicted rates therefore highlights how
often mis-predictions of baseline event rates influence power. Similar analyses were undertaken
using all RCTs with binary nonmortal primary outcomes.

Statistical analyses
We conducted unadjusted comparisons of proportions using x2 tests to examine the
differences in proportions of successful trials across trial characteristics. We used multivariable
regression to identify study-level characteristics associated with a trial’s being positive. For this
purpose, given limited degrees of freedom, we limited our assessments to the following trial
characteristics: (1) mortal vs. nonmortal primary outcome, (2) funding source (3) single vs. 2-10
centers vs. > 10 centers and (4) type of intervention. Odds ratios (ORs) from a logistic regression
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and prevalence rate ratios (PRR) from a Poisson regression with a robust variance estimator are
presented since the ORs will overestimate relative risks with event (positive trial) rates >10%
(Deddens & Petersen, 2008).

Results
Our search identified 376 potential studies published between January 2007 and May
2013 (Figure 2.1). Of these, 146 met the pre-specified inclusion criteria. The most commonly
tested types of interventions were protocols (49%) and drug therapies (40%) (Table 2.3). Most
trials (92%) compared two intervention arms (max=5). Overall, 54 (37%) were positive, that is,
these RCTs demonstrated a significant difference between study groups in the primary outcome
as hypothesized (Table 2.3). In addition to the 21(14%) RCTs stopped early for safety or futility
an additional 4 RCTs (3%) revealed statistically significant findings of inferiority (i.e.,
effects contrary to the primary hypothesis).
The most common primary outcomes were measures of mortality over a specified time
period (27%), followed by outcomes related to healthcare associated infections (23%), ventilation
(21%) (e.g., time to extubation, ventilator-free days or required mechanical ventilation), and
quality (10%) (e.g., complications or adverse events). The incidence of positive trials varied
depending on the primary outcome. The success rates for trials using these four abovementioned outcomes were 10%, 58%, 43% and 50%, respectively. Two of the four positive
mortality trials were only significant after pre-specified adjustment (Jansen et al., 2010; Papazian
et al., 2010); thus, only 5% of these trials showed statistically significant differences in crude
mortality rates. Twenty-four of the 40 trials where mortality was the primary outcome studied 28or 30-day mortality. Five additional RCTs included a mortality endpoint as part of a composite
primary outcome with nonmortal measures and one RCT was powered on mortality despite being
listed as a secondary outcome; of these, one trial was positive.
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Figure 2.1. Analytic sample of published randomized clinical trials of critical care interventions

Potential adult critical care RCTs identified in 16 target journals potentially eligible for inclusion:
n=376

Reasons for exclusion:
Not a RCT = 28
Does not take place in an ICU or in an ICU patient population = 58
Outcomes are not clinical according to eligibility criteria = 116
Sub-analyses or post-hoc analyses of RCT data = 28

Critical care RCTs identified in adults abstracted: n=146

Critical care RCTs that studied a binary primary outcome: n=101




40 had a primary outcome of mortality over a specified time period
o n=34 superiority RCTs included information on their power estimate
(denominator for Figures 2.4 and 2.6)
o Reasons for exclusion (n=6)
 n=2, 2x2 factorial designs
 n=2, insufficient reporting
 n=2, cluster randomized trial
61 tested other nonmortal binary primary outcomes
o n=47 superiority RCTs included information on their power estimate
(denominator for Figure 2.5)
o Reasons for exclusion (n=14)
 n=6, insufficient or unclear reporting of results or analyses
 n=4, non-inferiority or equivalence designs
 n=2, three or more study arms
 n=1, 2x2 factorial design
 n=1, reported post-hoc power calculation
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Table 2.3. Characteristics of adult randomized clinical trials in critical care
Characteristic

N (%)

N (%) with a positive
primary outcome

Total
146 (100%)
Funding
No industry
80 (55%)
Some industry
42 (29%)
No funding / not reported
24 (16%)
Single center
54 (37%)
Multicenter
92 (63%)
10 or fewer ICUs
40 (27%)
11-25 ICUs
25 (17%)
>25 ICUs
27 (18%)
Type of intervention studied
Protocol
71 (49%)
Drug
59 (40%)
Device/ monitoring
5 (3%)
Other
11 (8%)
Primary target patient populations
General ICU
52 (36%)
Sepsis spectrum
22 (15%)
Cardiac critical care
17 (12%)
Acute lung injury/ ARDS
16 (11%)
Unit of randomization
Patient, surrogate, or family
137 (94%)
ICU (cluster randomization)
9 (6%)
Primary outcome (1 per trial, n=146 CCRCTs)
Mortality (e.g., Hospital, ICU, 28-day)*
40 (27%)
Infection related
33 (23%)
Ventilation related
30 (21%)
Quality (complications/adverse outcomes)
14 (10%)
Organ failure
8 (5%)
Composite outcome
7 (5%)
Delirium
5 (3%)
Hospital Discharge disposition (functional status)
3 (2%)
Length of Stay
3 (2%)
Smoking cessation
2 (1%)
Quality of sleep
1 (1%)
Most frequent secondary outcomes (multiple possible per RCT)
Mortality
ICU Mortality
In-hospital mortality
28 day
29-180 days
Ventilation
Duration of MV
Ventilator free days
Length of Stay
ICU length of stay
Hospital length of stay
Quality (Complications/adverse outcomes)
Infection related
Organ failure
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54 (37%)
26 (33%)
13 (31%)
15 (63%)
25 (46%)
29 (32%)
18 (45%)
6 (24%)
5 (19%)
30 (42%)
18 (31%)
1 (20%)
5 (45%)
30 (58%)
0
7 (41%)
2 (13%)
49 (36%)
5 (56%)
4 (10%)
19 (58%)
13 (43%)
7 (50%)
1 (13%)
2 (29%)
2 (40%)
1 (33%)
2 (67%)
2 (100%)
1 (100%)

47 (32%)
44 (30%)
29 (20%)
35 (24%)

4 (9%)
2 (5%)
4 (14%)
5 (14%)

55 (38%)
22 (15%)

12 (22%)
6 (27%)

93 (64%)
71 (49%)
60 (41%)
36 (25%)
17 (12%)

12 (13%)
5 (7%)
14 (23%)
8 (22%)
2 (12%)

The most common secondary outcomes across all RCTs were ICU (64%) and hospital
(49%) length of stay (Table 2.3).
Of the 122 (84%) trials that disclosed the funding source, 34% reported receipt of
industry funding, and 66% reported no industry funding. There was no relationship between
industry funding and the probability that a trial would be positive (33% vs. 31%, p = 0.9). The
remaining 24 trials did not disclose any sources of funding, and these were more likely to be
positive (63%, p = 0.005 for comparison with all studies reporting funding sources). Single center
RCTs (n=54) were less common than multi-center RCTs (n=92). However, multi-center RCTs
were less likely to be positive and the rate decreased as the number of participating ICUs
increased (p=0.03) in univariate analyses. In the multivariable regressions, RCTs that did not
report any funding source (OR=3.3, 95% CI: 1.2-9.4) and RCTs that did not study a primary
mortality outcome (OR=6.8, 95% CI: 2.1-22.7) were significantly more likely to be successful
(Figure 2.2).

Figure 2.2. Adjusted associations of selected RCT characteristics with positive primary outcomes

Notes: RCTs that included measures of morbidity or other clinical measures in the primary
outcome were not categorized as mortality trials.
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Power or sample size were discussed in 135 RCTs (92%), however, only 68% of these
studies cited prior research, a pilot study, or examination of other data (e.g., from the authors’
center) to justify the inputs used in calculating the required sample size (Table 2.4). A CONSORT
diagram portraying participant flow was reported in 119 RCTs (82%).

Table 2.4. Power and sample size characteristics of randomized clinical trials in critical care
n (%)
Characteristic
Number of RCTs
positive
Total
Included a consort diagram (patient flow)

146
119 (82%)

Rationale for power parameters (e.g., baseline rate,
92 (63%)

predicted delta, expected time to event)
Type of outcome
Binary outcome
Duration: (e.g., event free-days) or time-to-event
Rate (e.g., per 1,000 patient days)
outcome
Continuous
RCT stopped early

101 (69%)
35 (24%)

31 (31%)
16 (46%)

7 (5%)

6 (86%)

3 (2%)

1 (33%)

32 (22%)

Futility

12 (8%)

Safety

9 (6%)

Recruitment / logistical issues

11 (8%)

Power or sample size plan discussed, including cluster
trials
RCT reported a targeted a priori sample size
Recruited < 95% of target or stopped early due to
recruitment / logistical issues
Recruited 95-110% of target sample size or stopped

135 (92%)
130/135 (96%)
20/130 (15%)

4/20 (20%)

88/130 (68%)

36/88 (41%)

13/130 (10%)

4/13 (31%)

early for futility
Recruited > 110% of target sample size
Stopped early for safety reasons

9/130 (7%)
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A total of 101 (69%) RCTs used a binary primary outcome. Of these, 40 examined a
mortality outcome and 61 used other nonmortal outcomes (e.g., incidence of VAP). Twenty-three
of the 40 RCTs with mortality as a primary outcome explained the rationale for their predicted
treatment-associated mortality reduction. Thirty-four of these 40 RCTs reported the values for
their power calculation and specified that they were superiority trials (i.e., powered for a specific
treatment-associated mortality reduction). Of these 34 mortality endpoint superiority trials, three
were positive (two only after pre-specified adjustment), and 11 (33%) had non-significant absolute
treatment effects in the hypothesized direction that were larger than 3% (Figure 2.3).
Of the 61 RCTs with a primary nonmortal binary outcome, 47 were two-arm superiority
trials and reported the predicted treatment-associated reduction they used for their power
calculation (Figure 2.1). Of these 47 RCTs, 20 were positive and 27 were statistically non-

Figure 2.3. Expected versus actual treatment effect on mortality in 34 superiority trials where the
primary outcome was mortality
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Figure 2.4. Expected versus actual treatment effect in 47 superiority trials with a binary nonmortal primary outcome

significant, of which 12 (44.4%) observed absolute treatment effects in the hypothesized direction
that were larger than 3% (Figure 2.4).
Among the 33 superiority trials without adaptive control arms reporting expected control
group mortality rates, the actual control group mortality differed from the expected value by 7.5%
or more in 22 RCTs (Figure 2.5). Despite these frequent differences between expected and
observed control group mortality rates, this rarely accounted for a study's inability to detect a
given effect size as significant. For example, 12 (out of 30) negative mortality trials that tested for
superiority could have detected a 10% mortality reduction with the observed control group
mortality rate, compared with 13 such trials if the expected control group mortality had been
observed (Figure 2.6). Among the 46 (of 47) nonmortal superiority trials with a binary endpoint in
which expected control group rates were reported in the manuscripts, the actual control group
rate differed from the expected value by 7.5% or more in 21 RCTs. Similar to the aforementioned
23

Figure 2.5. Expected and observed rate of mortality in control arms in RCTs that tested the effect
of an intervention on mortality

Expected mortality rate in control arm
Observed mortality rate in control arm
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Figure 2.6. Simulation results of superiority trials where the primary outcome was mortality
assuming 80% power to find a treatment-associated mortality reduction of 3 to 15%
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results for mortality trials, misspecification of control group rates rarely accounted for a study's
inability to detect a given effect size as significant.

Discussion
This contemporary study of 146 RCTs published in the leading medical and critical care
journals yields several important findings. First, investigators choose a variety of primary
outcomes for trials of ICU-based interventions. Some of this heterogeneity is appropriate given
different anticipated effects of various interventions. However, the variation of endpoints selected
even among trials using some form of a mortality primary endpoint suggests little agreement on
the optimal outcomes in critical care. These data complement a prior study showing variability in
ventilation-associated outcomes in critical care RCTs (Blackwood et al., 2014). This lack of
standardized definitions and methods for assessing common outcomes poses challenges for
comparing and understanding differences between RCTs, replicating results, and conducting
meta-analyses.
Second, a majority of RCTs are “negative” in the sense that they do not demonstrate a
benefit from the tested intervention. This is particularly true when mortality is the primary outcome
(10% positive rate, or 5% if only crude rates are considered), with higher proportions of positive
trials when other outcomes are used (13-100% positive rate) (Table 2.3). Of note, a 5-10%
positive rate is roughly the rate that would be expected assuming a conventional type I error rate
of 0.05. A prior review of RCTs in both adults and children published in the journal Intensive Care
Medicine from 2000-2010 found an overall success rate of 48.8% (of 221 RCTs) (Latronico et al.,
2013), somewhat higher than our observed rate of 37% (of 146 RCTs). Additionally, two reviews
that focused on RCTs using mortality endpoints found success rates of 14% (10 of 72 RCTs
published before August 2006) (Ospina-Tascon et al., 2008) and 18% (7 of 38 RCTs published
from 1999-2009 in 5 major medical journals) (Aberegg et al., 2010), somewhat higher than our
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rate of 10%. Although it is possible that more trials are becoming negative over time, these
differences may also be attributable to variability in the journals sampled and the eligibility criteria
used to include RCTs. Because our study and all prior studies focused on published RCTs, the
true rates of successful trials are likely even lower.
The high rate of negative trials does not, itself, suggest a problem; a majority of trials may
“appropriately” fail to detect significant reductions in mortality. Such “true negatives” could arise if
more interventions being tested are truly ineffective, as may occur when a discipline matures.
Alternatively, such findings may be attributable to the fact that mortality in the ICU is heavily
determined by physicians’ decisions to withhold or withdraw life support (Garland & Connors,
2007), crowding out any plausible effect of an intervention. Finally, 10% or 20% of trials should be
negative by chance alone even when power is set to 90% or 80%, respectively.
Nonetheless, the present study suggests that in many cases, critical care RCTs, and
especially those studying mortal endpoints, have not been designed to identify realistic treatment
effects. For example, we find that in a majority of negative RCTs, the results move in the
predicted direction, often considerably so, yet fail to attain the predicted treatment effect upon
which the study was powered (Figures 2.3 and 2.4). This provides contemporary evidence in
support of the notion that investigators commonly select implausibly large treatment effects upon
which to base sample size requirements (Aberegg et al., 2010). Although the problem of
underpowered trials is certainly not unique to critical care, it does raise ethical concerns because
such trials expose research participants to the risks and burdens of research without being
(sufficiently) able to deliver on the purported benefits of expanding knowledge and improving
future care (S. D. Halpern et al., 2002; Luce et al., 2004).
A third and related finding is that investigators commonly err in predicting the baseline
event rate in their trials. With high-predicted background rates, large absolute risk reductions
might seem plausible to investigators because they would reflect more modest relative risk
reductions (Sackett et al., 1997). However, we find that control group mortality rates are often
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considerably lower than predicted, which could make such large effects improbable. For instance,
it may be unreasonable to assume that an intervention predicted to bring mortality down to 30%,
assuming a base rate of 40%, would also reduce mortality to 10% if the base rate turned out to be
20%. Thus, as the baseline mortality rate declines, there will invariably be diminishing marginal
returns for any intervention – i.e., a lower proportion of potentially save-able patients.
Despite the possibility that over-predictions of control group event rates would contribute
to critical care RCTs being negative, this appears to be only a minor piece of the problem. We
found that even when large errors were made in predicted baseline mortality, this rarely changed
whether a trial would or would not have detected a given difference as significant. This may be
attributable to a counterbalancing phenomenon whereby as the baseline rate moves away from
50%, the sample size required to detect any given difference on an absolute scale decreases.
Studies of secular declines in mortality rates for common pathologies, such as done with
multicenter RCTs in sepsis (Stevenson et al., 2014) and acute lung injury (Spragg et al., 2010),
could better inform control group mortality rates, and also guide selection of more reasonable
treatment effects when designing future RCTs. Further, event-driven adaptive trial designs, such
as utilized in the PROWESS-SHOCK trial (Ranieri et al., 2012), that adjust (by increasing sample
size) to lower than expected mortality in the control group offer an attractive solution to this issue.
Additional strategies for improving trial success might include use of pre-specified
covariate adjustment (Hernandez et al., 2004; Roozenbeek et al., 2010; Roozenbeek et al., 2009)
[e.g., see Jansen and colleagues (Jansen et al., 2010)], larger target sample sizes, and more
realistic and conservative treatment effect expectations (Scales & Rubenfeld, 2005) (Table 2.5).
Additionally, innovative trial designs, such as Bayesian adaptive trials, may be particularly
valuable for assessing drug therapies (Angus & van der Poll, 2013; Spragg et al., 2010).
Regarding endpoints, some have questioned the conceptual propriety of using mortality as an
endpoint for research or quality assessment on seriously or critically ill patients (Holloway & Quill,
2007). Although many experts believe that mortality is the ultimate patient-centered outcome for
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critically ill patients, others have called for greater use of nonmortal clinical endpoints (Ferguson
et al., 2013; Spragg et al., 2010). Unfortunately, nonmortal endpoints face several threats to
validity including, but not limited to, ascertainment bias (measurement error) and the limits of
commonly used statistical methods for addressing the competing risks and informative dropout
attributable to high ICU mortality rates. Indeed, our observation that RCTs of nonmortal endpoints
were more likely to be positive may be an artifact of these measurement and analysis problems.
Ongoing methodological work designed to offer new critical care outcome measures that
incorporate mortality into the assessment of ICU length of stay or post-ICU quality of life may
ultimately offer optimal approaches for quantifying the effects of interventions in the ICU.
This study has limitations. First, we only calculated power and detectable differences for
trials using binary endpoints. We considered methods to assess effect sizes of trials employing
continuous or time-to-event outcome such as ventilator-free days or time to extubation. However,
potential effect size cutpoints (i.e., Cohen’s d, Glass’s Δ or Hedges’s g), are all based on
assumptions of normally distributed data. Because we found these assumptions unrealistic for
most critical care outcomes, and the inputs difficult, if not impossible to back calculate from the
published findings, we limited our power assessments to trials using binary outcomes. Second,
our review was limited to adult critical care RCTs published in 16 selected journals. Third, since
we relied on published data (and online supplements when available), changes in journal
requirements over time may have contributed to certain reporting omissions (e.g., funding
information or CONSORT diagrams). Fourth, important design issues such as allocation
concealment, blinding or masking and ascertainment bias were not assessed. Finally, while we
implemented an exhaustive search with oversight from a medical librarian, it is conceivable that
our search strategy did not identify all eligible trials.
In summary, we believe greater dialogue is needed to determine the utility of nonmortal
outcomes to patients, providers, and payers, and to identify elements of trial design and analysis
that are associated with the significance of results (Naylor & Llewellyn-Thomas, 1994; Spragg et
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al., 2010). Rather than abandoning RCTs, the results suggest opportunities for designing critical
care trials more efficiently. Actionable first steps might include consensus building among the
critical care community (including journal editors) regarding a minimum core outcome set
(Blackwood et al., 2014; Young et al., 2012), methodological work to improve strategies for
measuring these outcomes, and closer scrutiny of submitted manuscripts to ensure an “honest”
power calculation, which should in turn encourage more realistic trial design.
In the subsequent chapters we examine some of these considerations by focusing on
nonmortal outcome measurement and analysis.
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Table 2.5. Selected recommendations for critical care trial design
Domain
Hypothesis
Recommendations to potentially improve design



Study
population

Treatment-effect
heterogeneity might lead
to a diluted effect estimate
because while
interventions work for
certain patients, others
are too sick and/or have
too many competing risks
for death for singular
interventions to be of
benefit.

Participant
accrual and
retention

RCTs are sufficiently
powered but patient
attrition leads to
appreciable postrandomization losses so
that the intention-to-treat
analyses are highly
conservative.







Stratified randomization.
Pre-specified severity of illness adjustment
when estimating treatment effects (Hernandez
et al., 2004).
Stratification of trial results based on severity
of illness at baseline (Kent et al., 2008; Kent &
Hayward, 2007).
Adaptive trial designs (e.g., using biomarkers
to stratify patients into more homogeneous
subgroups (Angus & van der Poll, 2013),
event-driven adaptive trials (Ranieri et al.,
2012), or starting trials with several arms and
then adjusting sample sizes (Friede & Kieser,
2006) or narrowing arms based on observed
interim safety and efficacy data (Lewis et al.,
2013)).
Incorporation of patient attrition estimates
when making sample size calculations.
Improved models of informed consent (Scales,
2013) and potentially incentives for research
participation (S. D. Halpern, 2011a).



Increased meta-studies to better inform control
arm event rates (e.g., (Stevenson et al.,
Even when the target
2014)).
sample size is achieved
 Use of more realistic and conservative
Statistical
and retained, RCTs may
predicted treatment effects when estimating
power
be insufficiently powered
sample sizes.
calculations to detect relatively small
 Use of continuous outcomes when possible.
but important effects on
 Reconstruction of binary endpoints into
appropriate outcomes.
categorical endpoints to improve statistical
efficiency (McHugh et al., 2010; Roozenbeek
et al., 2010).
 Consensus development among trial groups
and intensivists about follow-up periods and
definitions of outcomes for specific conditions
to support comparisons across trials (e.g.,
Outcome measures are
meta-analysis) (Blackwood et al., 2014; Young
Outcome
inappropriately specified
et al., 2012).
or analyzed.
 Novel methods for handling right-censoring
due to deaths in analyses of quality of life and
other nonmortal outcomes (Rosenbaum,
2006).
The following references contributed ideas presented in this table: (Aberegg et al., 2010; Angus
et al., 2010; Annane, 2009; McAuley et al., 2010; Ospina-Tascon et al., 2008; Reade & Angus,
2009; Rubenfeld & Abraham, 2008; van Meurs et al., 2008).
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CHAPTER 3. NONMORTAL TRIAL ENDPOINTS: EMPIRICAL FRAMEWORK FOR A CASE
STUDY OF INTENSIVE CARE UNIT LENGTH OF STAY

Rationale for examining nonmortal endpoints
The objective of this chapter is to summarize the conceptual framework and empirical
methods used for the statistical simulation studies that are reported in Chapters 4 and 5. These
two chapters focus on nonmortal endpoints, with ICU LOS as a case illustration.
As a sizeable proportion of ICU-based RCT study subjects die before the trials are
completed (Mebazaa et al., 2016), a mathematical tension has emerged for future trial design.
If researchers continue to choose mortality as an endpoint (thus powering trials for a difference in
proportions), trials will either have to enroll substantially larger patient populations, or pursue
increasingly larger treatment effects. The former option potentially limits the feasibility of trials,
and the latter option increases the risk of missing small, but clinically important treatment effects.
Accordingly, several thought leaders and trial consortiums in critical care have advocated
the importance of validating patient-centered and clinically relevant nonmortal endpoints (Opal et
al., 2014; Spragg et al., 2010; Young et al., 2012). However, lack of agreement concerning
specific definitions and analytic methods for these outcomes may limit the external validity and
applicability of RCT findings (Blackwood et al., 2014; Contentin et al., 2014). Therefore, Chapters
4 and 5 seek to contribute knowledge on the current scope of methods used to assess nonmortal
endpoints, and illustrate potential modifications in interpretation that may achieve the stated goal
of improving the design and interpretation of critical care trials.

Intensive care unit length of stay
In Chapter 2, we found that ICU LOS is the most frequently reported primary or
secondary outcome among ICU-based trials. ICU LOS is a promising nonmortal trial endpoint for
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at least five reasons. First, LOS is easily measured from claims data and electronic health
records. Second, LOS is important to patients and their families, whose quality of life is impacted
by hospitalization and intensive care (Iwashyna, 2010). Third, LOS is relevant to all patients, in
contrast to other common nonmortal ICU trial outcomes, such as ventilator-free days and organfailure-free days. Fourth, LOS is a practical measure of resource allocation that can be quantified
in economic terms (Cooke, 2012; Dasta et al., 2005; Kahn et al., 2008; Rapoport et al., 2003).
Fifth, continuous outcomes such as LOS generate greater statistical power than dichotomous or
categorical outcomes, thereby facilitating detection of effective treatments (Altman & Royston,
2006; McHugh et al., 2010).

Designing a simulation study of intensive care unit length of stay
In our conceptual framework of ICU LOS, we identified several processes, including
overall mortality, mortality differences, and procedural factors that may affect the total duration of
ICU stay of a study cohort. In Chapters 4 and 5, we isolate these processes and generate
subsequent distributions of ICU LOS to examine how the interpretation of treatment effects for
continuous, duration-based endpoints can be challenged by issues related to informative
censoring from mortality and measurement error. While each analysis focuses on distinctly
different aspects of interpreting LOS treatment effects, the empirical approach for each is
interrelated. Therefore, we present the general summary used for each analysis here to avoid
redundancy within each chapter.
Both of these research studies rely on the analysis of simulated (i.e., hypothetical or
artificial) ICU LOS distributions. Simulating a LOS distribution that reflects potentially real-world
settings is not a straightforward process. For example, the ICU LOS for a given trial population
consists of a heterogeneous mix of subjects who died and those who survived. Consequently,
ICU LOS may represent two very distinct clinical outcomes; for some subjects, ICU LOS may
represent time to death, and for others, represents time to clinical improvement. Understanding
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how changes in mortality (Chapter 4) or measurement error among survivors (Chapter 5) can
impact the interpretation of a LOS estimate requires that the analyst can isolate these processes
and to keep other processes identical so that any remaining sources of variability are removed.
To achieve the inferential aims of each chapter, we cumulatively employ three different
approaches to data generation. For each of the data generation processes, we use the survsim
package in STATA (College Station, Texas), which uses a competing risk multistate model to
generate time-to-events (Beyersmann et al., 2009; M. J. Crowther, 2011; M.J. Crowther &
Lambert, 2012). In each setting, we manipulate cause-specific hazards for death and discharge to
generate ICU LOS. Utilizing this data generation process, we then assume an intervention could
modify the overall LOS distribution through three mechanisms based on the goal of the
simulation:
1. LOS among survivors and LOS among decedents are independent, such that a
change in one does not impact the other.
2. LOS among survivors and LOS among decedents are correlated, such that an effect
of an intervention among survivors could reduce the fraction of mortality (i.e.,
mortality rate) in the treatment arm because patients are discharged faster, but an
intervention does not impact the time-do-death (i.e., hazard) among those who die.
3. LOS among survivors and LOS among decedents are correlated, such that an effect
of an intervention that modifies the time-to-death among decedents could also modify
the time-to-discharge, as saved patients would shift into the risk-set for discharge and
then be exposed to the discharge hazard.
Each approach has merits when the goal is to understand how different sources of bias
can manifest in treatment effect estimates. We employ the third approach in Chapter 4. In this
analysis we are precisely interested in how changes in mortality can modify summary estimates
and statistical comparisons of ICU LOS. While the duration outcome in these chapters is LOS,
such a decision is semantic, such that any duration could be selected for the hypothetical
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simulation (i.e., duration of mechanical ventilation). Accordingly, in this analysis we assume that
an intervention does not change LOS among those patients who would always survive. We then
modify the cause-specific hazard for death and quantify how statistical comparisons of LOS
change using a range of statistical models found to be used in the systematic review. Therefore,
we are able to gain insight into how mortality can modify LOS distributions and thus, statistical
comparisons.
In Chapter 5, the goal is to estimate how factors extraneous to a subject’s clinical state
can also impact treatment effect estimates. We utilize the first and second data generation
frameworks above to achieve this goal. We chose to use these two settings because the choice
of either permits differences to exist between the total number of survivors, who are all potentially
exposed to this form of measurement error. First, we assume that there is a group of patients who
will always die regardless of their intervention arm, as well as a group who will always survive. A
clinical analog might be an intervention that reduces the rate of an infection that is not lifethreatening. As a result, a shorter LOS is observed among treated patients since the control arm,
on average, requires additional ICU care until resolution of infection. However, survival is not
affected. We call this the ‘principal stratification’ framework as we only modify LOS among those
in the cohort who are discharged alive from the ICU. In the second setting, we alter the setting
above such that the intervention, in reducing ICU LOS, indirectly reduces overall mortality in the
treatment arm among a subgroup of patients who would have died in the ICU in the previous
framework. Thus, we conceptualize the trial population to be comprised of those who will always
survive, those that would have died in the ICU but since they were discharged faster survive their
ICU stay, and those who would always die during their ICU stay. The intervention only impacts
the first two patient types, thereby reducing the overall ICU mortality rate, but having no impact on
the time to death among those who die. Stated another way, such an intervention only passively
reduces ICU mortality by reducing risks associated with being in the ICU (e.g., sepsis, blood
stream infection) because treated subjects are discharged faster. This aligns with the
conventional ‘competing risk’ framework.
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CHAPTER 4. HETEROGENEITY IN THE DEFINITION AND ANALYSIS OF INTENSIVE CARE
UNIT LENGTH OF STAY IN CRITICAL CARE TRIALS

This chapter has been submitted for publication. The suggested citation is:
Harhay MO, Ratcliffe SJ, Small DS, Suttner L, Crowther MJ, Halpern SD. Heterogeneity in
the definition and analysis of intensive care unit length of stay in critical care trials. (Under
review)
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Introduction
This chapter focuses on empirical and interpretive challenges that may arise when
interpreting ICU LOS when mortality is differential between study arms. Since critically ill patients
commonly die, comparisons of nonmortal endpoints must properly account for these deaths either
empirically or conceptually. Otherwise, the truncation of follow-up or censoring from death may
cause nonrandom missing outcome data, potentially eroding the assurance of unbiased inference
and thus interpretation when summarizing differences between study arms (Brock et al., 2011;
Hernán & Robins, 2016; McConnell et al., 2008; Schoenfeld et al., 2002).
While some prior work has considered statistical models to account for this potential bias
(Checkley et al., 2010; Chiba & VanderWeele, 2011; Deslandes & Chevret, 2010; Hayden et al.,
2005; Resche-Rigon et al., 2006; Yang & Small, 2016), this paper focuses on understanding how
nonmortal outcomes (using ICU LOS as an example) are examined in practice, and on gauging
the potential impact of small, non-significant treatment-associated mortality effects on the results
of typical analyses of nonmortal trial outcomes. To accomplish these goals, we extend the
systematic review from Chapter 2 to assess the variability in the definitions and measurement of
LOS in published RCTs, with specific attention to the methods used by researchers to manage
competing events (i.e., death) when comparing nonmortal endpoints between study arms.
Second, we use statistical simulations to assess the biases that may be generated from the most
commonly used analytic methods found in the review. Finally, we use these findings to guide
recommendations for reporting and analyzing LOS as an outcome in ICU-based RCTs, with
extensions to other longitudinal, nonmortal outcomes.

Methods
Systematic review
For the present analysis, we extended the database detailed in Chapter 2 by two years,
such that it now spans the period from 01/2007 through 06/2015. For each trial, the abstractors
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(MOH and LS) identified whether LOS was the primary or secondary outcome, the definition
provided by the authors, the statistical methodology used to compare LOS between treatment
arms, and how the LOS distribution was reported (e.g., survivors only).

Illustration of interpretive bias through simulation
Building conceptually from recent critical care simulation studies and expert roundtables
(Iwashyna et al., 2015; Mebazaa et al., 2016; Sjoding et al., 2015), we designed three simulation
settings to illustrate how different mortality effects that may occur in reality could impact the
interpretation of LOS. In setting 1, there was no treatment-associated mortality reduction (i.e., we
simulated a perfectly null effect). In setting 2, the intervention imposed a constant effect over time
(i.e., proportional hazards) such that the probability of a mortality reduction was equal for all
patients. In setting 3, we isolated the treatment-associated mortality reduction to the simulated
patients with a LOS in the upper tertile (i.e., time-dependent treatment effect) so as to reflect the
possibility that the treatment might help only the sickest patients who tend to have longer LOS
(Moitra et al., 2016; Zimmerman et al., 2006). Although we simulate beneficial mortality effects of
treatment, identical results would manifest had we imposed the mortality reduction on the control
arm. Thus, the results of this approach also apply to cases of harmful treatment effects.
As outlined in Chapter 3, to isolate the impact of these potential treatment-associated
mortality effects on the interpretation of LOS comparisons, the simulated data are set such that
the intervention would truly have no effect on LOS if all patients survived. Specifically, the
parameter controlling the treatment effect was set to zero in the discharge sub-model, and set to
give the imposed mortality reduction (2.5% or 5.0%) in the death sub-model with administrative
censoring at 30 days. Thus, any observed LOS effect would be due to chance or the bias
produced by the mortality effect. Such bias could arise if the treatment extended patients’ LOS by
saving them, or if it lengthened time-to-death among some patients who nonetheless die.
We express the primary outcome of interest of all simulations as the “interpretive error
rate,” defined as the percentage of simulations in each setting reporting a statistically significant
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difference in LOS between the intervention and comparator arm. The expected interpretive error
rate due to chance is 5% using two-sided statistical tests with alpha=0.05.
To enhance the range of trials to which our results may apply, we adjusted four
parameters in each of the three settings. First, the control-group 30-day mortality was set to 30%
or 10%, representing relatively high and relatively low in-hospital mortality rates for modern
RCTs. Second, we imposed an absolute mortality reduction of 2.5% or 5.0% in the intervention
arms. We chose these effects because they would be clinically important, but most ICU-based
RCTs would fail to detect them as statistically significant. Third, we examined short (median 3
days, interquartile range [IQR]=1.5-4.5) and long (10 days, IQR=5-17) LOS distributions, guided
by ICU-based RCTs where LOS was the primary outcome (Ali et al., 2011; Amrein et al., 2014;
Casaer et al., 2011; Kerlin et al., 2013). Finally, we simulated the total sample size as 250 or
1000 patients (125 or 500 patients per arm). This approach yields 2 x 2 x 2 x 2 = 16 simulations
to be run in each of the three settings. However, we only applied a 2.5% absolute mortality
reduction in settings in which the control-group mortality rate was 10% because a single ICU
intervention would be unlikely to produce a 5% absolute reduction in mortality from 10%, and if it
did, this effect would commonly reach statistical significance. Simulated data were generated as
outlined in Chapter 3 (approach 3) using the survsim package in STATA, and 1,000 Monte Carlo
replicates were used in each simulation setting.
We did not examine the statistical properties of ICU free-days or of changing the
valuation of LOS to be the longest LOS or never discharged because the valuation of death as a
specific LOS value has subjective elements that are beyond the scope of this work.
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Results
We identified 193 eligible RCTs among ICU patients from 2007-2015. Of these, 150
RCTs (78%) reported on ICU LOS, with 132 of these trials explicitly reporting ICU LOS as an a
priori outcome. In 6 trials LOS was specified as the primary outcome, and in 126 it was specified
as a secondary outcome.

Definition and measurement of LOS
In 70 (47%) RCTs reporting on ICU LOS, insufficient details on the definition or
measurement of LOS were provided to identify how ICU LOS was measured. Of the remaining 80
(53%) RCTs, at least either the start or end time was reported by the authors (n=54, 36%) or we
believed one of these times could be reasonably deduced (n=26, 17%) based on the text and
detail related to the study design or other trial outcomes. In 70 trials that had a reported or
deducible “start time,” LOS measurement began at: a) the time of ICU admission (47%) b) the
time of randomization or trial enrollment (34%), or c) the time of initiation of the intervention (7%).
In the remaining 11% of trials, more than one start time was reported or two or more of these
times appeared to overlap. In 70 trials that had a reported or deducible LOS “end time,” these
times were specified as: a) ICU discharge and/or death (93%), or b) time of resolution of critical
illness (7%). As a result, ICU LOS could represent six distinct durations based on the current
literature (Figure 4.1). In addition, precision in the reported units of LOS was also quite variable,
with 60 (40%) trials reporting LOS in 24-hour periods without rounding to the nearest day, and 77
(51%) trials reporting LOS as “days” without clarifying if days were calendar days or 24-hour
periods. The remaining 9% reported LOS in hours (n=13).

Statistical analysis of ICU LOS
The statistical analysis used to compare LOS between study arms was unclear or not
identifiable in 3 of the 150 trials and 10 trials reported to use >2 distinct statistical models. One
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Figure 4.1. Variation in the reported definition of intensive care unit length of stay

trial assessed LOS as a binary outcome (i.e., prolonged LOS [LOS > 4 days] or not), and the
remaining 146 trials treated LOS as a continuous outcome. Based on the information provided by
the authors we concluded that 75 trials compared LOS using a non-parametric rank-based test,
with 61 of such trials explicitly stating the use of this method. Similarly, we concluded that 51 trials
used a linear parametric model; 32 of these explicitly stated this. Twenty-three trials used time-toevent methods, specifically a Cox proportional-hazards model (n=14) or a log-rank test (n=9).

Treatment of LOS among decedents
In the analysis of LOS, 92 trials (61%) reported the assessment of a pooled LOS
distribution without discussion or statistical consideration of mortality, 12 (8%) studies assessed a
stratified sample of survivors and 4 trials (3%) reported both a pooled and stratified result (these
approaches are detailed in Table 4.1). The remaining studies reported at least one LOS value or
approach that explicitly modeled or acknowledged mortality. A version of the ICU free-day
outcome was reported in 19 (13%) trials, with the valuation of death (always equal to zero days)
explicitly reported in ten trials. Nine trials (6%) changed the value of LOS to be the longest LOS
(n=2) using a non-parametric model or to never be discharged in a time-to-event model (n=7).
Nine trials (6%) (including two that also used an infinite time approach) reported using a time-toevent model explicitly stating to have censored LOS at the time of death while the remaining did
not clearly report their censoring approach.
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Table 4.1. Leading approaches used to account for mortality in the analysis of length of stay

Approach

Conceptual and empirical
issues

Consequence

Hypothetical trial
scenario that would
complicate approach

LOS distribution is composed
of treatment effects that may
impact overall measures of
dispersion but limited to a small
number of patients.

Estimate from
statistical test may
be hard to interpret
or misleading in
isolation.

Patients saved by a
treatment may
experience a longer
LOS that would
impact the
interpretation of the
statistical
comparison.

Construct and
contrast a
composite endpoint
that includes both a
value for death and
LOS (i.e., ICU freeday metric where
those who died are
assumed to have 0
ICU free-days).

Valuing death inserts
subjectivity to statistical
analysis and fundamentally
changes the causal question.
ICU free-day metric does not
have real world translation.

Estimates “net
effect” of
intervention.
Disentangling effect
of an intervention on
either death or LOS
is underpowered
and limited by issues
related to
multiplicity.

Events of interest
move in opposite
directions, e.g.,
decreasing mortality
and elongating LOS.

Contrast the LOS
distribution among
survivors only.

Survival may be affected by the
treatment. Thus, it is a postrandomization variable.
Conditioning on this can erode
randomization inference and
reduces study power.

Estimate from
statistical test may
be hard to interpret
or misleading in
isolation.

Saved patients are
among the sickest,
and thus experience
longer LOS that
would impact the
interpretation of the
statistical
comparison.

Estimate from
statistical test may
be hard to interpret
or misleading in
isolation. May cause
selection bias unless
assumptions of the
model can be
proven.

Heterogeneous
treatment effects
based on severity of
illness or
comorbidities.

Estimate from
statistical test may
be hard to interpret
or misleading in
isolation.

Upon death, which
will happen often in a
trial, patients are
removed from risk
set.

Contrast pooled
LOS distribution of
survivors and
decadents together
without
acknowledging
death.

Contrast time-to-live
discharge in a time
to event model and
treat mortality as a
form of nonadministrative
censoring.

Contrast time-to-live
discharge in a time
to event model and
set the time to event
to be infinite or
longest possible
LOS.

Risk set subsequent the first
death comprises a new subset
of patients who have not
previously died or been
censored. Thus, balance of
confounders assumed by
randomization is potentially
eroded. Statistical model
assumes a “latent” LOS for
censored patients – i.e., the
LOS that patients who die are
assumed to have had if they
had lived, which is unknowable.
Patients do indeed have a
chance of discharge in time-toevent model. Thus the
statistical density of the time-toevent distribution is flawed,
intentionally, and does not
consider death as a competing
event for discharge.
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Simulation study
The validity of our simulation approach was confirmed by the results in the control setting
(setting 1) in which we assessed rates of interpretive errors using the most commonly reported
methods of analyzing LOS data when there was no treatment effect on LOS or mortality. In this
setting, LOS differences appeared nearly 5% of the time, as would be expected by chance (Panel
A, Figures 4.2 & 4.3), and were not impacted by the overall mortality rate (not shown).
By contrast, all simulations were susceptible to interpretive errors when the treatment
reduced mortality by 2.5% or 5.0%. The magnitude of bias depended on the total sample size,
magnitude of the mortality effect, and the patients to whom the effect applied (i.e., uniform versus
heterogeneous treatment effects) (Figures 4.2-4.6). When the mortality treatment effect was
uniform (equal), we found that summary comparisons of the entire sample (which ignore
differences between deaths and live discharges) performed the worst, with little difference
between parametric and non-parametric comparisons. Similarly, we found high rates of
interpretive errors across settings when these statistics were applied only to survivors. This effect
was most pronounced when the treatment-associated mortality effect was isolated to the sickest
patients (setting 3). Overall, time-to-event (discharge) analyses with censoring for death provided
the lowest interpretative error rates. However, separate biases created by informative censoring
may cloud the interpretation of results in time-to-event models (see discussion).
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Figure 4.2. Percent of simulations exhibiting interpretive errors (primary setting, short LOS,
treatment effect of 2.5%)

Notes: Based on chance approximately 5% of the simulations would be expected to be
statistically significant, denoted by bars at -2.5% and 2.5% since we are using a two-sided test.
Settings: Control group mortality rate of 30%, short LOS.
Figure 4.3. Percent of simulations exhibiting interpretive errors (primary setting, long LOS,
treatment effect of 2.5%)

Notes: Based on chance approximately 5% of the simulations would be expected to be
statistically significant, denoted by bars at -2.5% and 2.5% since we are using a two-sided test.
Settings: Control group mortality rate of 30%, long LOS.
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Figure 4.4. Percent of simulations exhibiting interpretive errors (sensitivity analysis, control group
mortality of 10%, uniform treatment effect of 2.5%)

Notes: Based on chance approximately 5% of the simulations would be expected to be
statistically significant, denoted by bars at -2.5% and 2.5% since we are using a two-sided test.
Settings: Control group mortality rate of 10%, long & short LOS.
Figure 4.5. Percent of simulations exhibiting interpretive errors (sensitivity analysis, control group
mortality of 30%, uniform treatment effect of 5%)

Notes: Based on chance approximately 5% of the simulations would be expected to be
statistically significant, denoted by bars at -2.5% and 2.5% since we are using a two-sided test.
Settings: Control group mortality rate of 30%, long & short LOS.
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Figure 4.6. Percent of simulations exhibiting interpretive errors (sensitivity analysis, control group
mortality of 30%, heterogeneous treatment effect of 5%)

Notes: Based on chance approximately 5% of the simulations would be expected to be
statistically significant, denoted by bars at -2.5% and 2.5% since we are using a two-sided test.
Settings: Control group mortality rate of 30%, long & short LOS,

Discussion
This study documents large variability in how LOS is defined and measured in critical
care RCTs, and demonstrates the importance of accounting for the interplay between treatment
effects on mortality and duration of illness when reporting nonmortal endpoints. Several specific
results yield recommendations for the future measurement, analysis, and reporting of ICU LOS.
First, we identified a lack of consensus regarding how best to conceptualize ICU LOS.
For instance, LOS was variably defined as time to discharge or death, as the time to live
discharge, or in other ways. Similarly, few trials clarified the start or end time of their LOS
measurement, and those that did showed a lack of consensus among three potential starting
times (the time of admission, randomization, or intervention). Such variability limits the ability to
compare interventions’ effects on LOS across trials. Similar problems arise from the noted
variability across trials in the scale of LOS reporting (i.e., calendar days versus 24-hour periods
without rounding versus hours), which may influence the magnitude of measurement errors.
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Second, we identified at least five distinct analytic approaches that were commonly used
to compare LOS between treatment arms in modern ICU-based trials (Table 4.1). These
variations in statistical methods are not merely technical considerations, but rather lead to the
testing of fundamentally different research questions. The most common approach is to contrast
the overall LOS distributions in each treatment arm, without accounting for mortality. Our
simulations suggest that this may generate misleading results in the context of small mortality
effects that are commonly observed in trials, even when these effects are themselves not
statistically significant. This degrades the ability to differentiate interventions that seem to
lengthen LOS due to beneficial, albeit perhaps underpowered mortality effects, versus those that
truly lengthen LOS without such corresponding benefits.
The other four commonly used approaches acknowledge the potential bias that
differential mortality can create, but their use raises other interpretive challenges (Table 4.1).
First, assessment of LOS among survivors reduces analytic sample sizes, which may be small in
critical care trials to begin with. Additionally, such restriction can yield misleading results if a
treatment shifts very sick patients from the “deceased” cohort to the “survived” cohort, where they
may contribute an unusually long LOS (Lin et al., 2014). Setting 3 of the simulation showed that
this approach can be especially problematic in the common cases in which treatment effects are
not uniform (Iwashyna et al., 2015).
Second, investigators may use a time-to-event model that estimates the time to live
discharge. Although censoring on death is likely superior to ignoring it altogether, such censoring
assumes that death is random and non-informative. This assumption is almost certainly
untenable (D. R. Cox et al., 1992), as patients’ acuities and comorbid conditions are related to
both their probability of dying and their LOS if they survive. Thus, the probability of censoring may
be time-dependent. If so, censoring could introduce bias despite randomization (Aalen et al.,
2015). A third approach values death as a fixed LOS for decedents. The most frequent valuation
approach uses an ICU free-day method, where LOS is set equal to the maximum follow-up time
minus ICU LOS for live discharges and 0 for decedents (Schoenfeld et al., 2002). This approach
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quantifies the “net-benefit” of a composite clinical outcome, although it lacks a clear translation
into clinical or economic benefit without separating the mortality and LOS components. Assessing
potential interpretative errors when using ICU free-days would require a complex assessment of
patient preferences as well as disparate treatment effects to fully evaluate their utility (e.g.,
increase in mortality among some patients and a decrease in LOS among others) and thus are
not included in our current study.
A similar consideration regarding the “value” of death is raised in the fourth approach with
changing LOS to be the longest observed LOS or treating the patient as never being discharged if
they died during the study period. In a time-to-event framework this raises potential empirical
issues due to the intentional distortion of the at-risk sample over time that needs to be better
understood to avoid unintended introduction of another empirical bias. A more recently proposed
approach that surmounts some of these conceptual problems is to code LOS as the longest
possible LOS (infinite time), and use non-parametric tests to compare LOS distributions among
treatment and control groups (Lin et al., 2014). Simulations using this approach suggest that it
can accommodate a range of values for death, such as coding it at the 80th percentile of the LOS
distribution or as the worst possible LOS (Lin et al., 2014). Thus, the approach enables
investigators to assess the possibility that the conclusions to be drawn may be sensitive to how
patients value death versus prolonged ICU stays. This approach is also flexible in that it enables
investigators to estimate treatment effects on the median LOS, 75th quantile of the LOS, or any
other point in the distribution (Lin et al., 2014). However, further experience with this approach is
required to determine whether it will be acceptable to and understood by key stakeholders.
Until such experience is gained, and based on the systematic review and simulations
presented in this manuscript, we recommend general standards for reporting LOS (Table 4.2) that
are more general than previously published recommendations for free-day outcomes (Contentin
et al., 2014) and broadly applicable to nonmortal outcomes. In addition, researchers may
consider using more recently developed alternative statistical inference methods (Checkley et al.,
2010; Deslandes & Chevret, 2010; Resche-Rigon et al., 2006), based on their inferential
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objectives in primary or secondary analyses. Finally, if longer follow-up after ICU discharge is
available (e.g., 6-month or 1-year mortality), principal stratification methods may be considered to
report nonmortal treatment effects (Chiba & VanderWeele, 2011; Hayden et al., 2005; Yang &
Small, 2016).

Limitations
A limitation of the systematic review portion of this study is that the categorization of what
authors had done in their trials was limited by differential reporting practices by authors as well as
standards and requirements at different journals (e.g., publication of trial protocols) which may
have impacted our ability to accurately document the LOS definitions and analytic methods. For
example, it is possible that many trials utilized detailed and standardized definitions and
measurements of LOS, but did not fully report them. This may be particularly true when LOS was
a secondary outcome measure. While this is unlikely to change the overall interpretation of the
results, this reality is important as the CONSORT standards for outcome reporting should apply
equally regardless of the journal, and researchers pursuing meta-analyses and systematic
reviews would encounter similar barriers when aggregating trial results. Thus, this limitation as
well as the issues we highlight remain important to promote the generalizability and aggregation
of knowledge from individual trials.
Second, though we sought to be exhaustive, it is possible that our search did not identify
some published trials. Such omissions are unlikely to have been systematic, and so would not be
expected to alter any of our conclusions.
Third, the simulation studies we presented were intentionally non-exhaustive of all
potential ICU trial settings. Statistical simulation studies provide a unique lens to model
hypothetical trial scenarios, and we have chosen a limited set of illustrative scenarios to
understand if missing or truncated outcome data can bias how we assess interventions in the
ICU. Many other scenarios are conceivable in an actual trial, such as those that include a
treatment effect on LOS directly. These cases were not modeled in our simulations. However, the
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goal of this manuscript was to highlight prevalent problems that could be created due to small
changes in mortality due to an intervention, rather than to provide an exhaustive accounting of the
magnitudes of these problems in all possible scenarios. Future work may help to understand
better the specific cases in which the magnitudes of the general biases we report are likely to be
most extreme, as well as understanding how simultaneous changes in the risk of death, disease
progression, and time-to-discharge among different patients can obscure or exaggerate effect
sizes reported in trials. Finally, different data generation processes and assumptions may lead to
different interpretations of the simulations.

Conclusion
Although ICU LOS is commonly used as an outcome measure in ICU-based RCTs, it is
inconsistently reported and analyzed. Problems with heterogeneity of outcome use and definition
are not limited to critical care, as documented in prior assessments of Cochrane reviews and
ClinicalTrials.gov entries (Hirsch et al., 2013; Tovey, 2011). The present study shows how these
choices may impact the interpretation of trial results. While challenging empirically and
conceptually, we propose that researchers could employ some simple practices in reporting trial
results to aid in their interpretation and synthesis. More granular reporting of mortality throughout
the duration of follow-up, with reporting at the exact time the nonmortal measure is assessed,
would help assess the risk of biased interpretation. Employing predefined secondary analyses
with novel statistical approaches, such as the aforementioned rank-based method (Lin et al.,
2014) and joint modeling approaches (Deslandes & Chevret, 2010), would enable experience to
be gained with these methods so as to determine whether they ought to become standard.
Finally, even very basic, but often ignored practices such as reporting the start- and end-time
used to define LOS and the values of LOS applied to those patients that die during follow-up
would greatly improve the interpretation of nonmortal endpoints in ICU-based RCTs.
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Table 4.2. Recommendations for reporting and analyzing nonmortal endpoints in critical care
trials

Domain

Problem identified in review
Trials reporting start and end times varied in
their definitions, and many do not report any
definition at all.

Recommendation
Clear indication of the start and
end time of the LOS
measurement.

Trials predominantly report LOS in "days."
Calendar days and 24-hour periods are
Granularity and specificity in the
different, and can further vary based on the
Measurement
measurement of LOS.
abovementioned issue of start and end times.
This potentially adds measurement error.
A version of the ventilator free-day was used
for ICU free-days, however, the treatment of
death and follow-up period was not well
defined in certain trials.

Detailed definition of composite
outcomes that include LOS.

Many trials simply state that nonparametric or
parametric statistical models were used
Stating exact model used to
without any further detail. It is unclear in
compare LOS between study
some trials which model was used to
arms.
generate the p-value.

Analysis

Similar to the issues noted for ICU free-days,
values applied to death are sometimes used
but not clearly stated.

Clearly stating assumptions of
statistical analysis related to the
treatment of LOS among
decedents (e.g., censoring).

The analytic sample assessed is not always
the full trial population. If survivors only are
analyzed it may not be clear which mortality
cut-off was used to define this group (e.g.,
ICU, hospital, or 28-day mortality).

Cleary stating which patients
were included in the analysis.

Mortality is often reported at a few discrete
time points (e.g., 28 or 60 days) or without
clarity of total follow-up time (e.g., ICU
mortality). This makes it difficult or impossible
to assess trials for the potential of interpretive
bias in the reporting of nonmortal endpoints if
non-differential mortality occurs.

Report mortality rates at more
granular time periods (e.g., 7,
14, 21, and 28 days).

Though the ideal or “correct”
method for statistical inference
is unclear, utilizing secondary
Most trials do not execute sensitivity analyses
methods such as competing
using advanced statistical methods.
risk, principal stratification, or
joint statistical models can help
researches assess their results.
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CHAPTER 5. MEASUREMENT ERROR IN INTENSIVE CARE UNIT LENGTH OF STAY
ESTIMATES DUE TO PATIENT FLOW

This chapter has been submitted for publication. The suggested citation is:
Harhay MO, Ratcliffe SJ, Halpern SD. Measurement error in intensive care unit length of stay
estimates due to patient flow. (Under review)
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Introduction
In Chapter 4 we focused on potential bias and misinterpretation due to differential
mortality. In this chapter we focus on another issue. Specifically, when evaluating the effect of a
clinical intervention on LOS, one wishes to determine the intervention’s impact on the time
required for patients to become clinically ready for ICU discharge. Yet ICU-based RCTs typically
report total LOS, defined as time until actual discharge. Because most ICU discharges entail
patients transitioning to a step-down unit or general ward, factors such as bed availability and
clinical rounding schedules may impact actual discharge time, independent of patients’ illnesses
or the interventions they receive (Wagner et al., 2013).
In this paper we examine the epidemiology and implications of such ‘immutable time,’
which is termed as such because this time cannot plausibly be affected by most ICU-based
interventions such as pharmacotherapies or ventilation strategies (Figure 5.1). We first perform a
systematic review of ICU-based RCTs to identify studies that have defined ICU LOS using
discharge readiness as an end time rather than actual discharge. Next, using statistical simulation
informed by our own RCT and administrative data, we quantify the extent to which immutable
time may actually bias estimates of treatment effects across a range of possible trial scenarios.

Figure 5.1. Decomposition of length of stay in an intensive care unit

Total LOS
Start

End

time

time
Medical resolution of
critical illness
(medically ready to go)

Trial enrollment
or
randomization

Discharge order
initiated
(administratively
ready to go)
Physical
departure
from ICU
room

ICU
admission
Immutable period
of LOS

Modifiable period of LOS
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Immutable period
of LOS

Methods
Empirical framework
Information or measurement bias is a type of bias that results from measurement error
(Lash et al., 2009). We define immutable time as a research bias because the resulting measure
of LOS erodes the precision of statistical comparisons between study groups with the potential to
obscure small, but clinically relevant treatment effects, or to suggest a treatment effect that does
not exist. Below, we provide a framework for this problem. Specifically, we assume that
immutable time is a non-differential measurement bias of a continuous (but non-normally
distributed) variable.
The statistical model, 𝑌𝑖 = 𝑓(𝑋𝑖 ) + 𝜖𝑖 , represents a common analysis conducted in RCTs
to quantify the effect of an intervention, where 𝑌 is ICU LOS, and 𝑋 is a binary indicator for
treatment arm generally measured without error, and 𝜖𝑖 indicates stochastic error. A parameter,
𝛽, is used to quantify the difference between the intervention and control LOS. For example, in
the linear model 𝑓(𝑋𝑖 ) = 𝛼 + 𝛽𝑋𝑖 . However, in lieu of LOS based on patient readiness, 𝑌𝑖 , the
̃𝑖 = 𝑌𝑖 + 𝜈𝑖 , where 𝜈𝑖 is the
value of ICU LOS with immutable time, ̃
𝑌𝑖 , is measured, such that, 𝑌
immutable time unaffected by treatment arm. We assume 𝜈𝑖 is independent of 𝑋𝑖 and 𝜖𝑖 . Under
̃𝑖 = 𝑌𝑖 + 𝜈𝑖 = 𝑓(𝑋𝑖 ) + (𝜖𝑖 +
this framework, the additional bias term, 𝜈𝑖 , results in the following, 𝑌
𝜈𝑖 ) = 𝑓(𝑋𝑖 ) + 𝜃𝑖 , where 𝜃𝑖 is an error term that is biased by measurement error. In some trial
designs early immutable time may also occur between the time of ICU admission and exposure to
an intervention (Figure 5.1), and would effectively increase the mean and variability of the
immutable time distribution.
Given that immutable time is essentially random and likely independent of treatment arm
assignment, the analysis 𝑌𝑖 = 𝛼 + 𝛽𝑋 + 𝜖𝑖 (i.e., a linear model) should produce a correct
estimate of 𝛽 quantifying the difference (treatment effect) between treatment with a normally
distributed outcome and normally distributed measurement error. The statistical explanation of
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why non-differential measurement error of an outcome (𝑌𝑖 ) would not bias the estimated
treatment effect point estimate (𝛽̂) in linear model is as follows:

𝛽̂ =

𝐶𝑜𝑣(𝑌̃𝑖 , 𝑋𝑖 )
𝑉𝑎𝑟(𝑋𝑖 )

=

𝐶𝑜𝑣(𝑌𝑖 + 𝑣𝑖 , 𝑋𝑖 )
𝑉𝑎𝑟(𝑋𝑖 )

=

𝐶𝑜𝑣(𝛼 + 𝛽𝑋𝑖 + 𝜖𝑖 + 𝑣𝑖 , 𝑋𝑖 )
𝑉𝑎𝑟(𝑋𝑖 )

=

𝐶𝑜𝑣(𝛼̃, 𝑋𝑖 )
𝐶𝑜𝑣(𝑋𝑖 , 𝑋𝑖 )
𝐶𝑜𝑣(𝜖𝑖 , 𝑋𝑖 )
𝐶𝑜𝑣(𝜐𝑖 , 𝑋𝑖 )
+ 𝛽
+ 𝛽
+ 𝛽
𝑉𝑎𝑟(𝑋𝑖 )
𝑉𝑎𝑟(𝑋𝑖 )
𝑉𝑎𝑟(𝑋𝑖 )
𝑉𝑎𝑟(𝑋𝑖 )

= 𝛽

𝑉𝑎𝑟(𝑋𝑖 )
𝑉𝑎𝑟(𝑋𝑖 )

=𝛽
However, since neither ICU LOS nor immutable time, based on our empirical distributions
(Figures 5.2-5.5) is normally distributed, it is unclear if this attenuation of the treatment effect will
persist as variance may change with less predictability. Specifically, since classical measurement
error has focused largely on linear regression models with normally distributed measurement
error, it is not clear how immutable time could bias LOS treatment effect estimates.
With small treatment effects, it is possible that the measurement error will obscure
treatment effects due to the resultant reduction in power. In other words, the variance will be
larger than was presumed in calculating the required sample size. Further, as the size of a
treatment effect increases, the more favorable signal-to-noise ratio would tend to mitigate the
impact of this extra variance. Thus, we also hypothesize that the reduction in power due to
immutable time would be most important in studies in which clinically relevant treatment effects
are often numerically small, as is commonly true in ICU-based RCTs (Aberegg et al., 2010;
Harhay et al., 2014; Rubenfeld, 2015).
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Data analysis
Literature review
To identify trials accounting for time-to-discharge readiness in practice, we utilized the
same data abstracted for Chapter 4, focusing specifically on those reporting the end time of their
ICU LOS measurement.

Secondary data analysis
We examined daily, weekly, and yearly variation in discharge immutable time, defined
as LOSdischarge - LOSready-to-go (indicated by a bed request for the patient on a general ward), at our
institution using two data samples. First, we reassessed data from the SUNSET-ICU trial, an RCT
comparing outcomes among patients whose nighttime management was overseen by senior
intensivists who were physically present in the ICU versus at home and available by phone
(Kerlin et al., 2013). Subjects included all patients admitted to the medical ICU (MICU) of the
Hospital of the University of Pennsylvania during a one-year period (09/12/2011 to 09/12/2012)
(Kerlin et al., 2013). In this trial, for patients readmitted to the MICU within the same
hospitalization, only the first MICU admission was included. Next, we extracted data on all
patients admitted to the same MICU from 2010-2012 to examine LOS variations over several
years, and to assess all discharges, not just index admissions.

Simulation study
We performed a simulation study based on the results of our analyses of the SUNSET
trial data and of administrative data sets. First, we generated a LOSready-to-go distribution to
approximate the ICU LOS distribution in the SUNSET trial using a Weibull distribution (median
LOS of 2.5 days and IQR of 1.2-4.5). We assumed that the probability of death in the ICU was
10%, 20% or 40%.
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As detailed in Chapter 3, the goal of a simulation study is to isolate a specific process,
and to keep other sources of variability identical. To isolate the effect of immutable time in our
simulations, only the time to discharge was manipulated. To capture the potential variability of
different critical care interventions, we conducted a simulation study that generated data using
both a principal stratification framework where the fraction of deaths was identical in study arms
and a competing risks framework where the faster time to discharge resulted in a lower ICU
mortality rate among the treated (without modifying the hazard for death) (see Chapter 3 for
additional details). The objective of the two approaches was to assess how different LOS models,
which treat or value LOS among deaths differently, may be affected by immutable time. For
instance, in a time-to-event model LOS among those who die may be censored.
Second, we imposed hypothetical treatment effects of 0, 0.5, and 1 day at the median
LOSready-to-go for the treatment arm. Next, three immutable time distributions of increasing size
(medians of 8, 16 and 28 hours in settings 1, 2, and 3, respectively) and generated from a
gamma distribution were randomly added onto the LOS ready-to-go of survivors who were discharged
(Figure 5.2). Thus, for each simulated trial there was an unbiased time-to-discharge-readiness
̃𝑖 ). Setting 1 was based on late immutable
(𝑌𝑖 ), and three LOS distributions with immutable time (𝑌
time observed in the SUNSET Trial. Setting 2 was based on the longer distributions of late
immutable time from our administrative data. Setting 3 assumed the combination of setting 2 and
a median 12-hours of early immutable time between ICU admission and exposure to an
intervention. We examined the impact of immutable time using four statistical approaches for
comparing LOS that are commonly encountered in the literature as identified in Chapter 4.
Specifically, the following methods identified in Chapter 4 were examined:
1) nonparametric comparison (i.e., comparing the entire distribution with a Wilcoxon Ranksum test;
2) parametric comparison (i.e., comparing the means and standard deviation using ordinary
least squares linear regression or t-test);
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3) time-to-event model (i.e., Cox proportional hazards model of the time-to-discharge with
mortality as a censoring event); and,
4) ICU free-days, where LOS is re-calculated as 30 days - LOS for survivors, and patients
who die are given a fixed LOS of 0 free-days (Schoenfeld et al., 2002). ICU free-days are
then compared using a nonparametric statistical model.

Total sample size was varied across settings (200, 400, 600, 800, 1000 and 1500
patients) to reflect the range of sample sizes observed in the majority of ICU-based trials
identified in Chapter 2. All settings assumed an equal number of patients in each of the two study
arms (1:1 randomization), and used one thousand Monte Carlo replicates. Administrative
censoring occurred at 30 days. To quantify the potential effect of immutable time on the
interpretation of analytic results, we summarized the percentage of times a two-sided statistical
test in the three immutable time settings differed from the error-free-LOSready-to-go at the α=0.05
level. Replicates were classified as false-positive if the intervention generated an effect on LOS at
p<0.05 in the presence of immutable time but the same test yielded p≥0.05 in the absence of
immutable time. Replicates were classified as false-negative in the reverse situation.

Figure 5.2. Sample immutable time distributions used for the simulation study
A) Setting 1
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B) Setting 2

C) Setting 3

Notes: The figures are generated from a random data generation with a sample size of 500
(n=250 per treatment arm). A kernel plot is used to overlay the distribution. Data is generated
using a Gamma distribution with the following settings:
A) shape=2 scale=0.205. Approximate median of 8 hours.
B) shape=3 scale=0.25. Approximate median of 16 hours.
C) shape=5.24 scale=0.235. Approximate median of 28 hours.

58

Results
Literature review
Trial investigators explicitly mentioned the use of a time-to-discharge readiness definition
of LOS in 5 of 150 ICU-based RCTs (3%) in which LOS was a primary or secondary outcome
(Table 5.1). Two trials used a ready-to-go time that was defined by clinical criteria, and two did
not specify their criterion. In the fifth trial, the SUNSET trial, ready-to-go time was an
administrative time-point indicated in the electronic medical record at the time the order for
transfer from the ICU (indicating clinical readiness for discharge) was placed.
Table 5.1. Documented use of time-to-discharge readiness to compare ICU LOS between study
arms
Author

Definition

Outcome

Casaer et al.
(Casaer et al.,
2011)

The duration of time in the ICU was defined as the time from
admission of patients until they were ready for discharge.
Patients were considered ready for discharge as soon as all
clinical conditions for ICU discharge were fulfilled (i.e., no
more need for vital-organ support and receipt of at least two
thirds of caloric requirements as oral feedings) even if they
were not actually discharged that day. The ‘ready for
discharge’ day coincided with the actual day of discharge for
all patients except for 104/2328 (4.5%) patients in the lateinitiation group and 95/2312 (4.1%) patients in the earlyinitiation group.

Primary

Jakob et al.
(Jakob et al.,
2012)*

Length of study ICU stay was defined as time from
randomization to being medically fit for discharge or transfer
from the study ICU.

Secondary in both
trials.

Tritapepe et al.
(Tritapepe et al.,
2009)

ICU length of stay (time meeting fit-for-discharge criteria).
Patients were eligible for transfer out of the ICU when the
following criteria were met: SpO 2 >90% at an FIO2 <0.5 by
facemask, adequate cardiac stability with no
hemodynamically significant arrhythmia, chest tube
drainage <50 ml h-1, urine output >0.5 ml kg-1 h-1, no i.v.
inotropic or vasopressor therapy, and no seizure activity.

Primary

Length of stay as the time to request for a bed to a general
ward.

ICU LOS (time-todischarge) was
primary, ready-togo was a
secondary
definition.

Kerlin et al.
(Kerlin et al.,
2013)

*Two trials are reported in this publication
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Secondary data analysis
Among the 1,149 MICU discharges to another hospital unit or ward among SUNSET trial
participants during their index ICU admission, we observed a median ready-to-go time of 40.1
hours compared to 46.8 hours of time from admission to actual discharge (Figure 5.3). The
median difference between ready-to-go time and actual discharge (i.e., immutable time) was 5.1
hours (IQR 2.7 to 8.9 hours). The 90th, 95th and 99th percentile differences were 14.2, 21.7 and
50.2 hours, respectively.
From administrative data of all MICU patients at our center in calendar years 2010-12, we
identified 3,851 discharges from the MICU. The overall median immutable time was 7.0 hours
(IQR 4.3 to 11.1, 90th percentile=21.6, 95th percentile=29.5), and this displayed considerable
weekly, monthly, and yearly variation (Figures 5.4 & 4.5). More than half of all discharge requests
were placed between 8 and 9 am, during which time the MICU’s morning bed management
rounds occur (Figure 5.6).

Figure 5.3. ICU length of stay ending at time of bed request and actual discharge among patients
discharged in the SUNSET RCT
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Figure 5.4. Weekly variation of immutable time in the Medical Intensive Care Unit of the Hospital
of the University of Pennsylvania, 2010-2012

Notes: Weekly (n=156 consecutive weeks starting in January 2010 on the far left through to
December 2012 on the far right) distributions (boxplots) are calculated using administrative data
from electronic medical records. The figure summarizes 3,851 medical intensive care unit (MICU)
discharges, some of which are readmissions (i.e., one patient may contribute >1 discharges).
Black lines in the middle of the box indicate the weekly median value. The bottom and top of the
box represent the weekly interquartile range (IQR) (i.e., first and third quartile), respectively, and
the top and bottom of the whiskers extending from the box represent the largest or lowest value
not greater or lower than the IQR times 1.5 for each week. Dots above a weekly distribution
indicate a time longer than 1.5 times the IQR for that week. Gray shading indicates weeks during
peak flu activity in December, January, February and March according to the Centers for Disease
Control.
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Figure 5.5. Variation of immutable time by month of the year in the Medical Intensive Care Unit of
the Hospital of the University of Pennsylvania, 2010-2012

Notes: Monthly (n=36 consecutive months starting in January 2010 on the far left through to
December 2012 on the far right) distributions (boxplots) are calculated using administrative data
from electronic medical records. The figure summarizes 3,851 medical intensive care unit (MICU)
discharges, some of which are readmissions (i.e., one patient may contribute >1 discharges).
Black lines in the middle of the box indicate the monthly median value. The bottom and top of the
box represent the monthly interquartile range (IQR) (i.e., first and third quartile), respectively, and
the top and bottom of the whiskers extending from the box represent the largest or lowest value
not greater or lower than the IQR x 1.5 for each month. Dots above a monthly distribution indicate
a time longer than 1.5 times the IQR for that month. Gray shading indicates weeks during peak flu
activity in December, January, February and March according to the Centers for Disease Control.
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Figure 5.6. Cumulative radar frequency graph of the time of day that a request for discharge was
submitted and occurred (24-hour day)

Notes: The figure summarizes the time (using a 24-hour day where 0 is midnight and 23 is 11
pm) a discharge order was placed for 3,851 discharges in the calendar years of 2010 to 2012
(n=156 weeks). The numbers inside the intermediate circles indicate 5%, 15%, and 54% of the
total, with the latter representing 2,076 discharges requested between 8-9 am, when morning bed
management rounds occur. The second spike of the hour-of-bed-request curve, at roughly 5pm,
coincides with the typical timing of evening bed management rounds.
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Simulation study
When data were simulated with no treatment effect, with a few exceptions in the largest
immutable time setting (i.e., setting 3), less than 2-3% of replicates had an inferential mismatch
due to immutable time (Figure 5.7). In the presence of a treatment effect, the rate of inferential
mismatches varied considerably depending on the statistical model. Generally, inferential
differences between the unbiased and immutable time LOS tended to decrease as (i) sample size
increased, (ii) mortality rates decreased, and/or (iii) the magnitude of the treatment effect
increased relative to the median immutable time (Figures 5.7-5.13). For example, in settings that
simulated a half-day median reduction in LOS with a 20% mortality rate, false inference rates as
high as 5% in setting 1 and 15% in setting 3 were observed. In the settings with a full day LOS
treatment effect at the median, false inferences tended to be isolated to the smaller sample sizes
of 200 to 600. Inferential differences between the two data generation approaches became
apparent as mortality increased. The rank-sum test and linear regression models tended to report
mostly false-negatives and have higher overall false inferential rates under the competing risks
framework. The ICU free-day metric, which valued LOS as 0 for decedents, seemed to reduce
inferential errors as the mortality rate increased under the competing risks framework, but less so
under the principal stratification framework. The Cox time-to-event model exhibited higher, and
mostly false-positive, rates as overall mortality increased from 10% to 40% under principal
stratification data generation. These rates were much lower and isolated to small sample sizes in
the competing risks framework. In many cases, the false positive and false negative
interpretations result from small changes in the observed p-values relative to those that would
have been obtained in the absence of immutable time.
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Figure 5.7. Simulation results with no LOS reduction
A) 10% overall mortality rate

B) 20% overall mortality rate
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C) 40% overall mortality rate

Notes: S1, S2, and S3 indicate immutable time settings 1, 2, and 3, respectively, and correspond
with a median of approximately 8, 16, and 28 hours of extra immutable time (Figure 5.2). A false
positive is operationally defined for this study as a two-sided statistical test on the difference
between study arms with immutable time added finding a p-value <0.05 when the error-free LOS
distribution had a p-value ≥0.05. A false negative is operationally defined for this study as a twosided statistical test on the difference between study arms with immutable time added finding a pvalue ≥0.05 when the error-free LOS distribution had a p-value <0.05.
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Figure 5.8. Simulation results with 10% baseline mortality, 0.5 day LOS reduction at the median
A) Principal stratification data generation model

B) Competing risk data generation model

Notes: See footnote for Figure 5.7. Reported LOS reduction is at the median.
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Figure 5.9. Simulation results with 10% baseline mortality, 1 day LOS reduction at the median
A) Principal stratification data generation model

B) Competing risk data generation model

Notes: See footnote for Figure 5.7. Reported LOS reduction is at the median.
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Figure 5.10. Simulation results with 20% baseline mortality, 0.5 day LOS reduction at the median
A) Principal stratification data generation model

B) Competing risk data generation model

Notes: See footnote for Figure 5.7. Reported LOS reduction is at the median.
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Figure 5.11. Simulation results with 20% baseline mortality, 1 day LOS reduction at the median
A) Principal stratification data generation model

B) Competing risk data generation model

Notes: See footnote for Figure 5.7. Reported LOS reduction is at the median.
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Figure 5.12. Simulation results with 40% baseline mortality, 0.5 day LOS reduction at the median
A) Principal stratification data generation model

B) Competing risk data generation model

Notes: See footnote for Figure 5.7. Reported LOS reduction is at the median.
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Figure 5.13. Simulation results with 40% baseline mortality, 1 day LOS reduction at the median
A) Principal stratification data generation model

B) Competing risk data generation model

Notes: See footnote for Figure 5.7. Reported LOS reduction is at the median.
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Discussion
The increasing uptake of duration-based endpoints including ICU LOS in health services
research requires scrutiny of the various definitions, analytic approaches, and inherent biases of
these metrics. The present study provides several important findings regarding the awareness,
patterns, and measurement errors associated with ICU LOS. First, fewer than 5% of published
ICU-based RCTs in the modern era have reported using either a medical or administrative readyto-go definition of ICU LOS. Further, there is often a lack of specificity in the reporting of how ICU
LOS was measured or analyzed. Without details regarding how authors define LOS endpoints,
comparisons of results across trials and meta-analyses are intrinsically limited.
Second, we re-analyzed data from the SUNSET trial and found that participants
experienced a median of 5.1 additional hours (IQR 2.7 to 8.9 hours) of ICU time after their clinical
improvement was confirmed with a discharge order. This discharge immutable time varied widely
in a subsequent examination of our center’s administrative data over a three-year period where
we found a slightly longer median immutable time of 7.0 hours (IQR 4.3 to 11.1 hours).
Third, we found that even when simplifying the mechanics of ICU LOS in a simulation
setting, the addition of immutable time to hypothetical error-free LOS distributions can
unpredictably erode statistical inference regardless of the statistical model. In reality ICU LOS is
not a homogenous distribution, but rather one comprised of time to death and time to discharge
sub-distributions, with heterogeneous patient subgroups (and thus LOS) in both. An intervention
can impose complex changes to these various sub-distributions upon which immutable time adds
an additional layer of inferential complexity. In our controlled simulation settings, the principal
findings are that immutable time could lead to a wrong conclusion about the effect of an
intervention on time-to-discharge readiness. While this predominantly results in the dilution or
masking of a statistically significant decline in the simulated time-to-discharge readiness when the
total LOS was assessed, particularly with small sample sizes, immutable time could also result in
instances where the total LOS exhibited statistically significant differences not occurring in time73

to-discharge readiness. However, this was predominantly in the principal stratification framework
and the time-to-event model and likely attributable to how this model estimates the latent LOS of
censored individuals. Nevertheless, this suggests that non-differential measurement error may be
less predictable when both the underlying error-free and measurement error distributions are not
normally distributed as their combination can result in quantities that are dissimilar in terms of
mean, median, and variance. The resulting small changes in the p-values between the two
models can become magnified when statistical significance thresholds (i.e., 0.05) are imposed.
This has important implications for how interventions are evaluated in trials versus real-world
settings. First, it suggests that more than one modeling approach can better inform LOS
comparisons. Second, declines in time-to-discharge readiness may be important to determine the
efficacy of a treatment but different stakeholders may interpret small declines in this time that
don’t result in declines in total ICU LOS differently.
In interpreting this work, the implications of several modeling assumptions must be
considered. First, though useful for illustration, an important limitation of our simulation study is
the assumption that immutable time would be non-differentially added across arms. This
assumption may not be true in practice. For instance, in our analysis of three years of
administrative data from one MICU, we found that the duration of discharge immutable time
varied by week and year (Figures 5.4 and 5.5), suggesting immutable time may be differentially
added to patients treated in the same ICU over time. While this variation would likely become
evenly distributed between intervention arms over a sufficiently long recruitment period,
particularly if randomization was done within center, these variations could conceivably lead to
differential effects of immutable time across arms in some trials. Such differential effects could
further distort treatment effect estimates (Fuller, 2006; Hyslop & Imbens, 2001), unless center
and seasonal effects are assessed and accounted for analytically (Kahan & Harhay, 2015).
A second assumption that may not hold in clinical practice is that the effects of immutable
time would accrue consistently across patient subgroups. In fact, special patient populations may
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experience levels of immutable time that exceed the average for a given ICU (e.g., patients
requiring contact precautions, telemetry, or higher-level nursing observation may take longer to
discharge to appropriate ward beds). Thus, trials that accrue relatively larger proportions of such
patients may experience larger effects of immutable time on precision.
Third, setting 2 is potentially the most informative to consider how immutable time may
manifest in reality and while the third simulation setting can be informative for understanding the
impact of large immutable times, such times may not be observed in many real-world settings. In
trials there will be a point at which patients are randomized and enrolled (which may not always
be equivalent and may or may not be at the time of admission). Thus, while discharge immutable
time will almost always exist to some extent, the existence and size of early immutable time will
vary with different study designs and interventions or it may be directly related to inclusion criteria
(e.g., patients ventilated >48hours). Thus, there are two potential definitions of early immutable
time: (1) time in the ICU from admission, or (2) after meeting exclusion criteria but prior to
exposure to an intervention that should be considered when designing and analyzing a study.
Finally, the ready-to-go time at our center was commonly observed during predictable
times of day, immediately following morning and evening bed management rounds (Figure 5.6).
Although many ICUs employ similar strategies for reviewing admission and discharge priorities at
discrete times of the day, these patterns could limit the applicability of our simulation data to other
units. Specifically, although all patients declared “ready to go” at these bed management rounds
were truly eligible for discharge, having been granted that status by their physicians, some of
these patients were likely ready to go hours beforehand. Trials conducted in ICUs that more
frequently assess patients for discharge readiness may experience either longer or shorter
immutable time distributions (with heightened or reduced implications for statistical precision,
respectively). Such ICUs could experience longer measured immutable time if ward discharge
times are relatively constrained, in which case the longer gaps between the more accurately
measured ready-to-go times and actual discharge times would exacerbate immutable time. By
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contrast, if more frequent assessment enabled more efficient discharge practices, this would limit
the generation of immutable time.
There are some additional limitations to our analysis. First, other settings not
incorporated into the simulation study, such as longer LOS or impacts of an intervention on timeto-death sub-distribution of ICU LOS, may also impact LOS interpretation. Variations in the
precision and detail of reporting by authors as well as differential standards between journals may
have caused a small underestimation of measuring time-to-discharge readiness in practice in the
systematic review. For instance, we found published trial reports that used a standardized
criterion for ICU discharge, but appeared to measure ICU LOS through till discharge. Utilization of
standardized discharge criteria suggests awareness of immutable time bias, but it does not fully
remove it. More broadly, lack of clarity and insufficient adherence to the CONSORT transparent
reporting of trials statement standards of outcome definitions such that they are able to be
replicated is an important finding of this work, but also a limitation, highlighting the importance for
improved standardization and reporting of ICU LOS and other common outcomes.
In summary, LOS is an attractive endpoint for use in a wide range of healthcare
outcomes research because it is important to patients, families, and health systems and readily
quantifiable. Indeed, it is the most widely used secondary endpoint in ICU-based RCTs (Harhay
et al., 2014). While our study focused on LOS measurement error in the ICU, the immutable time
we identified is unlikely to be limited to ICU settings. Therefore, our results have potentially broad
significance and applicability for health services research. Thus, when utilizing duration endpoints
such as LOS, failing to consider or report definitions of the outcomes that are most plausibly
related to interventions may result in inconsistency across trials, reduced power, and potentially
even bias. These problems may be especially important in ICU-based RCTs, given the difficulties
of recruiting adequate sample sizes to identify realistic and clinically meaningful treatment effects
(Aberegg et al., 2010; Harhay et al., 2014; Rubenfeld, 2015).
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CHAPTER 6. CONCLUSIONS
There are several overarching conclusions that can be derived from this thematically
linked work examining endpoints in ICU-based RCTs. First, our extensive review of the literature
demonstrates a lack of standardized definitions and methods for reporting and comparing both
mortal (Chapter 2) and nonmortal (Chapters 4 and 5) endpoints in published, experiential critical
care research. This finding has several practical consequences. Primarily, as a result of a lack of
core and standardized outcomes, critical care researchers who are interested in examining the
same endpoint may in fact be asking different empirical questions, especially in regard to
endpoints measured in terms of duration. The result manifests in how trials are conducted and
reported and thus translated into clinical practice. It also confounds the ability of researches
attempting to confirm the external validity of RCT findings, understand differences in observed
effects between RCTs, and conducting meta-analyses. A second key finding of this work is that
trials of mortality infrequently show a mortality effect due to their sample size (Chapter 2), but the
small mortality differences that are observed have the potential to impact how nonmortal
endpoints are interpreted (Chapters 4 and 5). This highlights an important fact: non-significant
results do not indicate null results. We have shown that in simplified simulated settings these
issues can profoundly complicate the interpretation of trial results. In real-world settings when all
these issues are simultaneously occurring, the inferential complexity is likely intensified and
requires close examination of several factors to fully understand how an intervention has
impacted patients (Tables 4.1 and 4.2)
In the course of this work, we have identified several new questions that may serve as
the foundation for future research. For instance, though trials may adjust for prognostic variables
such as severity-of-illness to assess their outcomes, other sources of variation (i.e., treating
physician, ICU and hospital factors) are often not accounted for in statistical analysis. This
practice has consequences, particularly given the frequent recommendation that more patients
and centers should be included in ICU-based RCTs to increase sample sizes and generalizability
(Landoni et al., 2015). While the multicenter design increases the likelihood of attaining adequate
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sample sizes, the diverse characteristics that vary across ICUs, such as intensivist practice
patterns, protocols, or the acumen of trainees and staff can exert a powerful influence on patient
outcomes. Thus, I contend that primary endpoints should be adjusted, at a minimum, for patient
acuity and center effects in primary analyses. This is especially important when the contribution of
enrolled subjects differs across centers, and failure to account for center effects can lead to
complex and unpredictable type I or II errors when comparing trial arms (Kahan & Harhay, 2015;
Kahan et al., 2014; Kahan & Morris, 2013). A key focus of my future research will be on how to
correctly account for these potential drivers and confounders of patient outcomes.
A second research direction relates to identification of better endpoints for trials. In
Chapter 2, we describe that nonmortal endpoints have become common in ICU RCTs, but in
Chapter 4 we illustrate the point that nonmortal endpoints are interlinked with and confounded by
mortality. As a potential solution, the use of event-free-days as a composite outcome (whereby
death equals zero free-days) is gaining traction (Blackwood et al., 2014; Harhay et al., 2014;
National Heart et al., 2011; Rice et al., 2011) because this composite outcome offers more
statistical power than mortality endpoints (Schoenfeld et al., 2002) and also overcomes certain
biases associated with death-induced missing data (i.e., informative dropout), which can
complicate the interpretation of duration-based endpoints (see Chapter 4). However, traditional
analyses of free-day outcomes do not describe patient trajectories over time (Schoenfeld et al.,
2002) and disregard patient preferences, some of whom may choose death over different longterm care requirements (Rubin et al., 2016). Finally, when interventions influence mortality,
independent examination of the mortal and nonmortal endpoints is necessary, thereby limiting the
conceptual, inferential and statistical benefits of free-day metrics as an outcome (Cannon, 1997;
Freemantle et al., 2003; Schoenfeld et al., 2002; Tomlinson & Detsky, 2010).
There are several potential approaches to meet the need for better trial endpoints. The
first is to develop and validate a weighting within a composite outcome framework that accounts
for patients’ preferences for death over different disease and treatment states. The second
approach relates to the assessment of endpoints with more appropriate statistical methods. In
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this regard I am especially interested and actively pursuing research to study nonmortal
outcomes such as ICU free-days, fluid balance and sequential organ failure assessment (SOFA)
scores in a joint longitudinal and time-to-event framework. Joint longitudinal and survival
modeling methods uniquely permit the simultaneous assessment of the longitudinal nonmortal
endpoint (e.g., free-days over time) and the mortal endpoint in a single statistical model (Ratcliffe
et al., 2004). This approach represents a novel analytic method to incorporate data on informative
dropout that generates unbiased treatment effects and provides greater insight regarding patient
trajectories over time (Ratcliffe et al., 2004; Rizopoulos, 2012). Integrating a patient-centered
outcome into this longitudinal framework has great promise, as longitudinal statistical methods
wield much greater power, thereby potentially reducing needed sample sizes such that resources
can be redirected to improve and expand outcome measurement and follow-up. Research by my
colleagues has already broached the methodological (Lin et al., 2014) and patient-centered
elements (Rubin et al., 2016) of this important topic. Integrating patient-centered outcomes and
longitudinal data structures is a necessary and logical next step to make advances in the
development of meaningful and measurable patient-centered outcomes in critical care.

Concluding remarks
In conclusion, this dissertation consisted of three empirical analyses that focused on
describing the current landscape of ICU-based RCTs and illustrating the consequences of bias
and measurement error in the interpretation of trial results. Chapter 2 established the foundation
upon which Chapters 4 and 5 were built. Accordingly, the conclusions and recommendations of
Chapter 2 are even more relevant when the work is considered together. Dialogue and
agreement throughout the critical care community (including journal editors) that goes beyond
another “call-to-action” is needed. Indeed, a subspecialty-specific CONSORT guideline statement
may be warranted given the unique challenges identified and number of non-significant trials that
have been published. The International Forum for Acute Care Trialists (InFACT) is actively
pursuing similar endeavors on a smaller scale. Their work, for instance, is currently focusing on
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the identification and publication of a minimum core set of outcomes for ventilation and other
modality-specific interventions (Blackwood et al., 2014; Blackwood et al., 2015). Such a forum
would be most appropriate for developing a critical care CONSORT document. This dissertation
also highlights the need for methodological work to improve strategies for defining and measuring
nonmortal outcomes, in such a manner that trial results can be compared across numerous
centers and patient populations. To this end, the results from this dissertation and our
recommendations will hopefully have a positive, albeit incremental, impact on the future of trials in
critical care patients.
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